%@LANGUAGE="JAVASCRIPT" CODEPAGE="936"%>
|
ÎÄÕª££££
18F-2ÍÑÑõ-DÆÏÌÑÌÇÕýµç×Ó·¢É伯Ëã»ú¶Ï²ãɨÃè¶ÔÆÀ¼Û¿ÉÇгýÐÔ·ÇСϸ°û·Î°©µÄ׼ȷÐÔ¼°³É±¾Ð§ÒæÑо¿
Rosemary F. Kelly, MD; Thao Tran, BS; Amy Holmstrom, RN; Jozef Murar, MD; and Romualdo J. Segurola, Jr, MD From the University of Minnesota (Drs. Kelly, Murar, and Segurola, and Ms. Tran), Minneapolis, MN; and the Minneapolis Veterans Affairs Medical Center (Ms. Holmstrom), Minneapolis, MN. Correspondence to: Rosemary F. Kelly, MD, One Veterans Dr, CV Surgery (112), Minneapolis, MN 55417; e-mail: kelly071@umn. edu
Ä¿µÄ£ºÍ¨¹ý¶ÔÊÖÊõÇгý·ÇСϸ°û·Î°© (NSCLC) »¼ÕߵĻعËÐÔÑо¿£¬ÆÀ¹ÀÓ¦ÓÃ18F-2ÍÑÑõÆÏÌÑÌÇ (FDG) ×÷Õýµç×Ӷϲã (PET) ɨÃè½øÐÐ×ݸôÁܰͽá (MLNs) ·ÖÆÚµÄ׼ȷÐԺͳɱ¾Ð§Òæ¡£ Éè¼Æ£º»Ø¹ËÐÔÑо¿¶ÔÏóÊÇ2001Äê1ÔÂÖÁ2002Äê9Ô¼仳ÒÉ»òÒÑ֤ʵ»¼ÓÐNSCLC¡¢ÐиùÖÎÐÔÇгýÊõ µÄ90Ãû»¼Õß¡£ËùÓл¼Õß¶¼ÎÞ×ªÒÆ¡£90ÈËÖÐÓÐ69ÈËÐÐÐØ²¿FDG-PETÓ°Ïñѧ¼ì²éÒÔÆÀ¹ÀÆä²¡³Ì£¬Õâ 69ÈËΪ±¾Ñо¿µÄÖØµã¡£½«CTɨÃèÓëFDG-PET±È½Ï£¬ÆÀ¼ÛÏÂÁÐÖ¸±ê£º¼ì²â×ݸôÁܰͽá×ªÒÆµÄÃô¸Ð ¶È¡¢ÌØÒì¶È¡¢×¼È·¶È¡¢ÒõÐÔ¼°ÑôÐÔÔ¤²âÖµ¡£ÓÃ4ÖÖ·½·¨±È½ÏÓ¦ÓÃ×ݸô¾µºÍ (»ò) FDG-PETÐÐMLN·ÖÆÚÖ®¼äµÄ²îÒì¡£ ²â¶¨ºÍ½á¹û£º69ÈËÊõǰÐÐCT¼°FDG-PET¼ì²é£¬ÆäÖÐ32ÈËÐÐ×ݸô¾µ¼ì²é¡£¹²ÓÐ57ÈËÐпªÐØ×ݸô ÁܰͽáÇгýÊõ¡£CT¼°FDG-PET¼ì²éµÄÃô¸Ð¶È¡¢ÌØÒì¶È¡¢×¼È·¶È¡¢ÑôÐÔ¼°ÒõÐÔÔ¤²âÖµ·Ö±ðΪ46%¡¢ 86%¡¢78%¡¢43%ºÍ87%¶Ô62%¡¢98%¡¢91%¡¢89% ºÍ92%¡£ÐÐ×ݸô¾µ¼ì²éµÄ32Ãû»¼ÕßµÄÕï¶ÏÕýÈ·ÂÊΪ100%¡£³£¹æ½øÐÐ×ݸô¾µ¼ì²éÈÔÊǾßÓм«¸ßÃô¸Ð¶ÈµÄ×î¾¼ÃÓÐЧµÄ·½·¨¡£¶ÔCT¼ì²éMLNs ½á¹ûÕý³£µÄ»¼ÕßÐÐÑ¡ÔñÐÔFDG-PETɨÃè¿ÉÒÔÌá¸ßÎÞ´´·ÖÆÚµÄÃô¸Ð¶È¡£ ½áÂÛ£ºÓëµ¥ÓÃCT¼ì²éÏà±È£¬Ñ¡ÔñÐÔFDG-PETɨÃè¿ÉÌá¸ßÖ×Áö·ÖÆÚµÄ׼ȷ¶È£¬ÊÇNSCLCÊõǰ·ÖÆÚ µÄ³É±¾-Ð§Òæ½Ï¼ÑµÄ¸¨Öú¼ì²é¡£µ«¶ÔMLNs < 1 cmºÍÏÙ°©»¼Õߣ¬FDG-PETɨÃèÉв»ÄÜ´úÌæ×ݸô¾µ¼ì²é¡£ ¹Ø¼ü´Ê£º°©Ö¢·ÖÆÚ (cancer staging); °© (carcinoma); 18F-2ÍÑÑõ-DÆÏÌÑÌÇÕýµç×Ó·¢É伯Ëã»ú¶Ï²ãɨÃè (18F-2-fluro-deoxy-D-glucose PET scan); ·ÇСϸ°û·Î°© (non-small cell lung cancer)
£¨ÁõÓ± Ò룻ÁõÖ¾ У£© ¡¾Ó¢ÎÄÔ¼þÇë²ÎÔÄChest, 2004; 125: 1413-1423¡¿
×èÈûÐÔ˯ÃߺôÎüÔÝÍ£-ºôÎü²»È«×ÛºÏÕ÷Óë°×´ó¹Ó¸ßѪѹ
Francisco Garcia, PhD; Jose M. Pino, PhD; Alberto Alonso, MD; Miguel A. Arias, MD; Isabel Martinez, MD; Dolores Alvaro, MD; and José Villamor, PhD From Servicios de Neumologia (Drs. Garcia-Rio, Pino, Alonso,Alvaro, and Villamor), Cardiologia (Dr. Arias), and Bioquimica (Dr. Martinez), Hospital Universitario La Paz, Madrid, Spain. Correspondence to: Francisco Garcia-Rio, PhD, Alfredo Marquerie 11, izqda, 1 A, 28034 Madrid, Spain; e-mail: fgr01m@jazzfree. com
±³¾°£º×èÈûÐÔ˯ÃߺôÎüÔÝÍ£-ºôÎü²»È«×ÛºÏÕ÷ (OSAHS) ºÍ¸ßѪѹµÄ¹ØÏµ¿ÉÒò¶Ô¸ßѪѹËùÏµĶ¨Ò岻ͬ¶øÓÐËù²îÒì¡£ Ä¿µÄ£ºÌ½ÌÖOSAHS»¼Õß²¢·¢°×´ó¹Ó¸ßѪѹ (WCH) µÄƵÂÊ£¬·ÖÎöÁ½²¡²¢´æµÄÌØµã¡£ ²¡ÀýºÍ·½·¨£ºÑ¡ÔñÁ¬ÐøµÄ99ÀýOSAHS»¼ÕߺÍ20Àý½¡¿µ¶ÔÕÕÕߣ¬Óö๦ÄÜ˯ÃßÃè¼Çͼ¼à²âµÄͬʱ½ø ÐÐ24 h¶¯Ì¬ÑªÑ¹¼à²â (ABPM) ¼°Äò¶ù²è·Ó°·²â¶¨£¬Í¬Ê±×÷¶¯ÂöÑªÆøºÍ·ÎÈÝÁ¿²â¶¨¡£ ½á¹û£º45ÀýOSAHS»¼ÕßÕï¶ÏΪÕïÁÆÊÒ¸ßѪѹ£¬ÆäÓà54ÀýѪѹÕý³£¡£ÐÐABPMºó£¬45ÀýÕïÁÆ ÊÒ¸ßѪѹ»¼ÕßÖеÄ30Àý±»È·ÕïΪ³ÖÐøÐÔ¸ßѪѹ£¬Óà15Àý (33%) È·ÕïΪWCH¡£WCH»¼Õß˯Ãß¹ý³Ì·¢×÷ºôÎüÔÝÍ£¼°¾õÐѵĴÎÊý£¬ÓëѪѹÕý³£ºÍ³ÖÐøÐÔ¸ßѪѹ»¼ÕßÏà±È´ó´óÔö¼Ó¡£Ë¯Ãß²ÎÊý¡¢¹¦ÄÜ ÊÔÑé¡¢Äò¶ù²è·Ó°·µÈÔÚ¸÷OSAHS×éÖ®¼ä¾ùÎÞ²îÒì¡£ ½áÂÛ£ºOSAHS»¼Õß³£ºÏ²¢WCH£¬µ«ÁÙ´²±íÏÖ²¢²»¾ßÌØÕ÷ÐÔ¡£ ¹Ø¼ü´Ê£º¶¯Ì¬ÑªÑ¹¼à²â (ambulatory BP monitoring); ¸ßѪѹ (hypertension); ˯ÃߺôÎüÔÝÍ£ (sleep apnea); °×´ó¹Ó¸ßѪѹ (white coat hypertension)
£¨ÕÅÇà Ò룻ФºÍƽ У£© ¡¾Ó¢ÎÄÔ¼þÇë²ÎÔÄChest, 2004; 125: 817-822¡¿
Ô˶¯ºóÒì³£ÐÄÂʻָ´Óë·Î¹¦ÄÜÒì³£µÄ¹ØÏµ
Niranjan Seshadri, MD; Thomas R. Gildea, MD; Kevin McCarthy, RCPT; Claire Pothier, MS; Mani S. Kavuru, MD, FCCP; and Michael S. Lauer, MD From the Departments of Cardiology (Drs. Seshadri and Lauer,and Ms. Pothier) and Pulmonary Medicine (Drs. Gildea and Kavuru, and Mr. McCarthy), Cleveland Clinic Foundation,Cleveland, OH. Correspondence to: Michael S. Lauer, MD, Director of Clinical Research, Department of Cardiology, Desk F25, Cleveland Clinic Foundation, 9500 Euclid Ave, Cleveland, OH 44195; e-mail: Lauerm@ccf. org
±³¾°£ºÔ˶¯ºóÐÄÂʻָ´ (HRR) ÓëÃÔ×ßÉñ¾ÕÅÁ¦Ï½µºÍËÀÍöÂÊÏà¹Ø¡£COPD»¼Õß×ÔÖ÷Éñ¾ÕÅÁ¦ÓÐ¿É ÄÜ·¢ÉúÁ˱仯¡£±¾Ñо¿Ö¼ÔÚ̽ÌÖHRRÓë·ÎÁ¿¼Æ¼ì²âµÄ·Î¹¦ÄÜÖ¸±ê¼äµÄ¹ØÏµ¡£ ·½·¨£ºÑо¿·ÖÎöÁË627ÀýCOPD»¼Õߣ¬Æäƽ¾ùÄêÁä (58¡À12) Ë꣬65%ΪÄÐÐÔ£¬Æ½¾ùFEV1 (2.6¡À0.9) L£¬Õ¼Ô¤¼ÆÖµµÄ (80¡À20) %¡£ÆäÖÐ10%µÄ»¼ÕßÎüÈëb2ÊÜÌ弤¶¯¼Á£¬3%ÎüÈ뿹µ¨¼îÄÜÒ©Î 5%ÎüÈëÀà¹Ì´¼¼¤ËØ£¬4%¿Ú·þÇ¿µÄËÉ¡£1 yÄÚ·ÖÁ½´Î¶ÔËûÃǽøÐм«ÏÞÔ˶¯ÊÔÑéºÍ·Î¹¦Äܲⶨ¡£ÅųýÐÄÁ¦Ë¥½ß¡¢Ö²ÈëÆð²«Æ÷ºÍ·¿²ü»¼Õß¡£Òì³£HRRµÄ¶¨ÒåΪÔ˶¯ºóµÚÒ»·ÖÖÓÄÚÐÄÂÊϽµ¡Ü12´Î/min (Ô˶¯¸ººÉ³¬ÉùÐĶ¯Í¼¡Ü18´Î/min)¡£¸ù¾ÝFEV1 ʵ²âÖµÕ¼Ô¤¼Æ°Ù·Ö±È°Ñ»¼Õß·ÖΪ4×é¡£ ½á¹û£º229Àý»¼Õß (36%) ³öÏÖÁËÒì³£HRR¡£¸ù¾ÝFEV1ƽ¾ùÖµ»®·ÖµÄ4×黼Õߣ¬ÆäFEV 1·Ö±ðÕ¼Ô¤¼ÆÖµµÄ (54¡À11) %¡¢(74¡À3) %¡¢(87¡À4) %ºÍ (106¡À10) %¡£ÎÞÂÛÎüÑÌ»¹ÊÇ·ÇÎüÑÌÕߣ¬FEV1ʵ²âÖµÕ¼Ô¤¼ÆÖµ°Ù·Ö±ÈµÄ¼õµÍ¾ùÓëÒì³£µÄHRRÏà¹Ø¡£¶à±äÁ¿·ÖÎö½á¹ûÏÔʾ£¬Ó°ÏìÒòËØ°üÀ¨Ò©ÎïºÍ¹¦ÄÜÐÔ ·ÎÈÝÁ¿µÄ¸Ä±ä¡£Òì³£HRRµÄÔ¤²âÒò×Ó°üÀ¨FEV1Õ¼Ô¤¼ÆÖµµÄ°Ù·Ö±È (Ͻµ1¸ö±ê×¼²îµÄ±ÈÖµ±ÈУÕýֵΪ1.32£¬95%CIΪ1.07~1.65£¬ P=0.000 4)£¬¹¦ÄÜÐÔ·ÎÈÝÁ¿ÊÜËðÇé¿ö£¬ÄÐÐÔºÍÄêÁä¡£ ½áÂÛ£º·ÎÁ¿¼ÆÖ¸±êµÄÒì³£ÓëÒì³£HRRÏà¹Ø, Ëü·´Ó³ÁË×ÔÖ÷Éñ¾ÕÅÁ¦µÄ¸Ä±äÓë·Î¹¦ÄÜÊÜËðÏà¹Ø£¬ÕâÖÖ¹¦ÄÜÕϰ¿ÉÒÔÊÇ×èÈûÐÔ¡¢Ò²¿ÉÒÔÊÇÏÞÖÆÐԵġ£ ¹Ø¼ü´Ê£º×ÔÖ÷Éñ¾ÏµÍ³ (autonomic nervous system); ÂýÐÔ×èÈûÐԷμ²²¡ (COPD); ÐÄÂÊ (heart rate ); Ô˶¯ÊÔÑé (exercise testing ); ·Î¹¦ÄÜ (pulmonary function)
£¨¶Àöϼ Ò룻³Â±¦Ôª У£© ¡¾Ó¢ÎÄÔ¼þÇë²ÎÔÄChest, 2004; 125: 1286-1291¡¿
¶Ô630Ãû×èÈûÐÔ˯ÃߺôÎüÔÝÍ£×ÛºÏÕ÷Óë÷ýÖ¢»¼ÕßÏÂò¢Ç°ÒÆ ½ÃÖÎÆ÷ÖÎÁÆµÄÆÀ¼Û ¡ª¡ª ÄÍÊÜÐÔºÍÖÎÁƳɹ¦µÄÔ¤²âÒò×Ó
Marie Marklund, DDS, PhD; Hans Stenlund, PhD; and Karl A. Franklin, MD, PhD, FCCP From the Department of Orthodontics (Dr. Marklund), Umeå University; and the Departments of Public Health and Clinical Medicine, Epidemiology (Dr. Stenlund), and Respiratory Medicine (Dr. Franklin), University Hospital, Umeå, Sweden. Correspondence to: Marie Marklund, DDS, PhD, Department of Orthodontics, Umeå University SE-901 87 Umeå, Sweden; e-mail: Marie.Marklund@odont. umu. se
Ä¿µÄ£ºÆÀ¼Û¿Éµ÷ʽ¡¢µ¥Æ¬ÏÂò¢Ç°ÒƽÃÖÎÆ÷ÖÎÁÆ×èÈûÐÔ˯ÃߺôÎüÔÝÍ£Óë÷ýÖ¢µÄÄÍÊÜÐÔ£¬É¸Ñ¡ÖÎÁƳɹ¦ µÄÔ¤²âÒò×Ó¡£ Éè¼Æ£ºÇ°Õ°ÐÔÑо¿¡£ µØµã£ºUmea´óѧ£¬ºôÎü¿ÆºÍ¿ÚÇ»Õý»û¿Æ ¶ÔÏó£º1989Äê2ÔÂÖÁ2000Äê8Ô£¬¶Ô630Àý½ÓÊÜÖÎÁƵÄ×èÈûÐÔ˯ÃߺôÎüÔÝÍ£Óë÷ýÖ¢»¼ÕßÖеÄ619Àý (98%) ½øÐÐÁËËæ·Ã¡£ËûÃÇµÄÆ½¾ùºôÎüÔÝÍ£ÓëµÍÍ¨ÆøÖ¸Êý (AHI) Ϊ16 (0 ~ 76)¡¢Æ½¾ùÌåÖØÖ¸Êý (BMI) Ϊ28 (19 ~ 42)¡£ ²âÁ¿£º·ÃÊÓ¡¢ÎʾíÓëÕûÒ¹µÄ˯ÃߺôÎüÔÝÍ£¼à²â¡£»¼ÕßÑöÎÔλºÍ²àÎÔλAHI¡Ý10 ±»ÈÏΪÓÐ×èÈûÐÔ˯ÃߺôÎüÔÝÍ£¡£²àλAHI < 10¡¢ÑöÎÔλAHI¡Ý10±»È·¶¨ÎªÑöÎÔλÒÀÀµÐÔºôÎüÔÝÍ£¡£ ½á¹û£º619Àý»¼ÕßÖÐÓÐ148Àý (24%) ÖжÏÁËÖÎÁÆ¡£ÑöÎÔλºÍ²àÎÔλAHI < 10 µÄÅ®ÐÔ¿ÉÒÔÔ¤²âµ½½ÏºÃµÄÖÎÁƳɹ¦ÂÊ£¬±ÈÖµ±ÈΪ2.4 (P=0.01)¡£ÖжÈ×èÈûÐÔ˯ÃߺôÎüÔÝÍ£µÄÅ®ÐÔ»¼ÕßÖÎÁƳɹ¦µÄ±ÈÖµ±ÈΪ12 (P=0.04)£¬¶øÓбÇÈûÖ¢×´µÄΪ0.1 (P=0.03)¡£ÄÐÐÔÑöÎÔλÒÀÀµÐÔºôÎüÔÝÍ£»¼ÕßµÄÖÎÁƳɹ¦±ÈÖµ±ÈΪ6. 0 (P<0.001)£¬ÖжȺôÎüÔÝÍ£»¼ÕßΪ2.5 (P=0.04)£¬ÏÂò¢Ã¿Ç°ÒÆ1 mm±ÈÖµ±È½µµÍ1.3 (P=0.03)£¬ÌåÖØÃ¿Ôö¼Ó1 kg±ÈÖµ±È¼õÉÙ0.8 (P=0.001)¡£ ½áÂÛ£ºÏÂò¢Ç°ÒƽÃÖÎÆ÷ÊʺÏÓÚÅ®ÐÔ×èÈûÐÔ˯ÃߺôÎüÔÝÍ£»¼Õß¡¢ÄÐÐÔAHI < 10µÄÑöÎÔλÒÀÀµÐÔºôÎüÔÝÍ£»¼Õߺ͵¥´¿÷ýÖ¢»¼Õß¡£ÄÐÐÔ»¼ÕßÔÚÖÎÁÆÆÚ¼äÌåÖØÔö¼Ó»á½µµÍÖÎÁƵijɹ¦ÂÊ£¬Í¬Ê±ÐèÒª´÷½ÃÖÎÆ÷ ÔÙ´Î×÷˯Ãß¼à²âÒÔ×÷ÎªËæ·Ã¡£ ¹Ø¼ü´Ê£º½ÃÖÎÆ÷¾ß (activator appliances); ÏÂò¢Ç°ÒÆ (mandibular advancement); ±ÇÈû (nasal obstruction); ÐÔ±ð (sex); ˯ÃߺôÎüÔÝÍ£×ÛºÏÕ÷ (sleep apnea syndromes); ÑöÎÔ루supine position£©
£¨¶Àöϼ Ò룻³Â±¦Ôª У£© ¡¾Ó¢ÎÄÔ¼þÇë²ÎÔÄChest, 2004; 125: 1270-1278¡¿
¾Æ¤¶þ¼â°ê³ÉÐÎÊõ¿ÉÒÔ½µµÍ·çʪÐÔ¶þ¼â°êÏÁÕ»¼Õß ÑªÑ»·ÖÐѪ¹Üϸ°û𤸽·Ö×Ó- 1µÄŨ¶È
Mien-Cheng Chen, MD; Hsueh-Wen Chang, PhD; Shyh-Shiann Juang, MS;Hon-Kan Yip, MD; Chiung-Jen Wu, MD; Teng-Hung Yu, MD; and Cheng-I Cheng, MD From the Division of Cardiology (Drs. Chen, Yip, Wu, Yu, and Cheng), Department of Internal Medicine, Chang Gung Memorial Hospital, Kaohsiung; Department of Biological Sciences (Dr. Chang), National Sun Yat-Sen University, Kaohsiung; and Chia Nan University of Pharmacy and Science (Mr. Juang), Tainan,Taiwan, ROC. Correspondence to: Mien-Cheng Chen, MD, Division of Cardiology, Department of Internal Medicine, Chang Gung Memorial Hospital, 123, Ta Pei Rd, Niao Sung Hsiang, Kaohsiung Hsien 83301, Taiwan, ROC; e-mail: chenmien@ms76. hinet. net
±³¾°£ºÒÑÖª·çʪÐÔ¶þ¼â°êÏÁÕ (MS) »¼ÕßѪѻ·ÖÐ𤸽·Ö×ÓÈçѪ¹Üϸ°û𤸽·Ö×Ó-1 (VCAM-1) ºÍϸ°û¼ä𤸽·Ö×Ó-1 (ICAM-1) µÄŨ¶ÈÓÐËùÔö¸ß¡£È»¶ø£¬¾Æ¤Ðжþ¼â°ê³ÉÐÎÊõ (PTMV) ¶ÔMS»¼ÕßѪѻ·ÖеÄVCAM-1ºÍICAM-1Ũ¶ÈµÄÓ°ÏìÆù½ñÉÐδÓÐÑо¿±¨µÀ¡£ ·½·¨ºÍ½á¹û£º19ÀýÓÐÖ¢×´µÄMSÐÐPTMVÊõµÄ»¼ÕßÈë×éÁ˱¾Ñо¿ (´ËΪµÚ1×飬ÆäÖÐ15ÀýÓÐÂýÐÔ·¿²ü£¬4ÀýΪñ¼ÐÔÐÄÂÉ)¡£ÐÐPTMV ֮ǰÊÕ¼¯¹É¶¯¾²ÂöºÍ×óÓÒÐÄ·¿µÄѪ½¬£¬PTMV 1ºÍ4 wkºóÊÕ¼¯ÍâÖܾ²ÂöѪ½¬£¬Ó¦ÓùÌÏà¼Ð²ãøÁªÃâÒßÎü¸½·¨²â¶¨¿ÉÈÜÐÔ VCAM-1ºÍICAM-1µÄŨ¶È¡£Í¬Ê±£¬Ó¦ÓöàÆÕÀÕ°ëÊýѹÁ¦·¨ (Doppler pressure half-time method) ²â¶¨¶þ¼â°êÃæ»ý¡£ÁíÍ⣬ÎÒÃÇ»¹²â¶¨ÁË22Àý¶ÔÕÕ×黼Õß [14Àýñ¼ÐÔÐÄÂɵĽ¡¿µÖ¾Ô¸Õß (µÚ2×é) ºÍ8ÀýÂýÐÔ¹ÂÁ¢ÐÔ·¿²ü»¼Õß (µÚ3×é) ] µÄѪ½¬VCAM-1ºÍICAM-1Ũ¶È¡£ÓëµÚ2×é (580.9¡À208.0) ng/mL¼°µÚ3×é (716.4¡À221.6) ng/mLÏà±È£¬µÚ1×黼ÕßµÄѪ½¬¿ÉÈÜÐÔVCAM-1Ũ¶ÈÃ÷ÏÔÉý¸ß [(1 205.4¡À462.4) ng/mL, P<0.000 1]¡£ÔÚµÚ1×黼ÕßÖУ¬×óÐÄ·¿Ñª½¬¿ÉÈÜÐÔVCAM-1ºÍICAM-1Ũ¶ÈÓëÓÒÐÄ·¿¡¢¹É¾²Âö»ò¹É¶¯ÂöÖеÄŨ¶ÈûÓÐÃ÷ÏԵIJî±ð (VCAM-1, P=0.668; ICAM-1, P=0.232)¡£ÐÐPTMVºó¶þ¼â°êÄ¤Ãæ»ýÃ÷ÏÔÔö¼Ó [Êõǰ (1.08¡À0.14) cm2£¬Êõºó (1.48¡À0.33) cm2£»P < 0.000 1]¡£ÐÐPTMVºó×ó·¿Æ½¾ùѹÁ¦Ã÷ÏÔϽµ [Êõǰ (22.9¡À5.2) mmHg£¬Êõºó (17.7¡À6.0) mmHg£»P < 0.000 1]¡£PTMVºóÍâÖܾ²ÂöѪ½¬¿ÉÈÜÐÔVCAM-1Ũ¶ÈÃ÷ÏÔϽµ [Êõǰ (1 205.4¡À462.4) ng/mL£¬Êõºó1 wk (915.7¡À280.2) ng/mL£¬Êõºó4 wk (859.0¡À298.7) ng/mL£»P < 0.000 1]¡£ ½áÂÛ£ºÖÐÖØ¶ÈMS»¼ÕßÐÐPTMVºó¾²ÂöѪ½¬¿ÉÈÜÐÔVCAM-1 Ũ¶ÈÃ÷ÏÔϽµ¡£Ñª½¬ÖпÉÈÜÐÔVCAM-1Ũ¶ÈÔö¸ßÓëѪҺ¶¯Á¦Ñ§Òì³£Óйأ¬Óë·çʪ»î¶¯Î޹ء£ ¹Ø¼ü´Ê£º¶þ¼â°êÏÁÕ (mitral stenosis); ¶þ¼â°ê³ÉÐÎÊõ (mitral valvuloplasty); Ѫ¹Üϸ°û𤸽·Ö×Ó-1 (vascular cell adhestion modecule-1)
£¨»Æ´ºÆ¼ Ò룻ʩ»ÀÖРУ£© ¡¾Ó¢ÎÄÔ¼þÇë²ÎÔÄChest, 2004; 125: 1213-1217¡¿
ÎÞÑõѵÁ·¶ÔÄÒÐÔÏËά»¯¶ùͯ»¼ÕßµÄÓ°Ïì ¡¡¡¡¡¡¡ª¡ª Ò»ÏîËæ»ú¶ÔÕÕÑо¿
Peter H. C. Klijn, PhD; Annemarie Oudshoorn, MD; Cornelis K. van der Ent, MD, PhD; Janjaap van der Net, PhD; Jan L. Kimpen, MD, PhD; and Paul J. M. Helders, PhD From the Departments of Pediatric Physical Therapy (Drs.Klijn, van der Net, and Helders), Pediatric Gastroenterology (Dr.Oudshoorn), and Pediatric Pulmonology (Drs. van der Ent and Kimpen), Wilhelmina Children's Hospital, University Medical Center, Utrecht, the Netherlands. Correspondence to: Janjaap van der Net, PhD, Department of Pediatric Physical Therapy, Wilhelmina Children’s Hospital,University Medical Center, Suite KB02.056.0, PO Box 85090, 3508 AB Utrecht, the Netherlands; e-mail: J.vandernet@wkz. azu. nl
±³¾°£º¶ùͯµÄÌåÓý»î¶¯Ä£Ê½ÒÔ¶ÌÆÚÎÞÑõ»î¶¯ÎªÌØÕ÷¡£Ïà¶ÔÓÚÓÐÑõ»î¶¯¶øÑÔ£¬¶ÔÄÒÐÔÏËά»¯ (CF) ¶ùͯ»¼Õß½øÐÐÎÞÑõѵÁ·¸øÓèµÄ×¢Òâ²»¹»¡£±¾Ñо¿Ö¼ÔÚ̽ÌÖÎÞÑõѵÁ·¶ÔCF¶ùͯ»¼ÕßµÄÓ°Ïì¡£ Éè¼ÆºÍ·½·¨£º20Àý»¼ÕßËæ»ú·ÖΪѵÁ·×é [TG×飬11Àý£¬Æ½¾ù (13.6¡À1.3) Ë꣬ƽ¾ùFEV1 (75.2¡À20.7) %Ô¤¼ÆÖµ] ºÍ¶ÔÕÕ×é [CG×飬9Àý£¬Æ½¾ù (14.2¡À2.1) Ë꣬ƽ¾ùFEV1 (82.1¡À19.1) %Ô¤¼ÆÖµ]¡£TG×éÿÖÜѵÁ·2 d£¬Á¬Ðø12 wk£¬Ã¿´ÎѵÁ·³ÖÐø30 ~ 45 min¡£ÑµÁ·ÏîÄ¿°üÀ¨³ÖÐø20 ~ 30 sµÄÎÞÑõ»î¶¯¡£CG×éÔò²»¸Ä±äÆäÕý³£µÄÈÕ³£»î¶¯¡£ÑµÁ·½áÊø¼°Ëæ·Ã12 wkÔÙ´ÎÆÀ¹ÀÇûÌå¹¹³É¡¢·Î¹¦ÄÜ¡¢ÍâÖܼ¡Á¦¡¢¹ß³£µÄÌåÓý»î¶¯¡¢ÓÐÑõÓëÎÞÑõÔ˶¯±íÏÖÒÔ¼°Éú»îÖÊÁ¿µÈÏîÄ¿¡£ ½á¹û£ºTG×黼ÕßµÄÎÞÑõÔ˶¯ÄÜÁ¦¡¢ÓÐÑõÔ˶¯ÄÜÁ¦ºÍÉú»îÖÊÁ¿¾ùÓÐÏÔÖø¸ÄÉÆ£¬¶øÆäËû¹Û²ìÖ¸±êÔòÎÞ Ã÷ÏԱ仯¡£CG×éÒ²ÎÞÈκθÄÉÆ¡£Ëæ·Ã½áÊøºó£¬TG×éÖ»ÓÐÎÞÑõÔ˶¯ÄÜÁ¦ºÍÉú»îÖÊÁ¿Ã÷ÏÔ¸ßÓÚѵÁ·Ç° ˮƽ¡£ ½áÂÛ£ºÎÞÑõѵÁ·¶ÔCF¶ùͯ»¼ÕßµÄÓÐÑõÔ˶¯ÄÜÁ¦ (¾¡¹Ü²»³ÖÐø)¡¢ÎÞÑõÔ˶¯ÄÜÁ¦ºÍ½¡¿µÏà¹ØÉú»îÖÊÁ¿ÓÐÒ»¶¨µÄÓ°Ïì¡£Òò´Ë£¬ÎÞÑõѵÁ·Ó¦ÁÐΪCF»¼ÕßÖÎÁÆ´ëÊ©µÄÖØÒª×é³É²¿·Ö¡£ ¹Ø¼ü´Ê£ºÎÞÑõѵÁ· (anaerobic training); ÄÒÐÔÏËά»¯ (cystic fibrosis); ÓªÑø×´¿ö (nutritional status); ·Î¹¦ÄÜ (pulmonary function); Éú»îÖÊÁ¿ (quality of life)
£¨»Æ´ºÆ¼ Ò룻ʩ»ÀÖРУ£© ¡¾Ó¢ÎÄÔ¼þÇë²ÎÔÄChest, 2004; 125: 1299-1305¡¿
ÍíÆÚChagas²¡»¼ÕßµÄÔ˶¯ÐÔÄÜÓë¹Ç÷À¼¡
Maria Montes de Oca, MD; Sonia H. Torres, MD, PhD; José G. Loyo, MD; Francia Vazquez, MD; Noelina Hernandez, PhD; Begona Anchustegui, BS; and Juan J. Puigbo MD, PhD From the Pulmonary Division (Drs. Montes de Oca and Vazquez), University Hospital of Caracas, Central University of Venezuela; Section for Muscle Adaptation (Drs. Torres, Hernandez,and Ms. Anchustegui), Institute of Experimental Medicine,Cental Univercity of Venezuala; Centro Medico de Caracas (Dr.Loyo); and Cardiomyopathy Unit (Dr. Puigbó), University Hospital of Caracas, Caracas, Venezuela. Correspondence to: Maria Montes de Oca, MD, CCS 5150, PO Box 025323, Miami, FL 33102-5323; e-mail: mmdeoca@cantv. net
Ä¿µÄ£ºÆÀ¼ÛÍíÆÚChagas²¡ (ChD) »¼ÕßÍâÖܼ¡ÈâµÄ´úлºÍ×éÖ¯½á¹¹ÌØÕ÷£¬²¢Ñо¿ÕâÐ©ÌØÕ÷ÊÇ·ñÓëÔ˶¯ÐÔÄÜÓйء£ Éè¼Æ£ººá¶ÏÃæÑо¿¡£ µØµã£ºÄ³´óѧҽԺµÄÐ¡ÃÅÕï¡£ ¶ÔÏóºÍ·½·¨£ºÎÒÃÇÑо¿ÁË11Àý¢òÆÚ»¼Õߣ¬8Àý¢óÆÚ»¼ÕߺÍ11Àý½¡¿µÖ¾Ô¸Õß¡£ËùÓл¼Õß¾ù×÷Ô˶¯ÊÔ ÑéºÍÍâÖܼ¡Èâ»î¼ì£¬¶ÔÕÕ×éÒ²×÷ͬÑùµÄ¼¡ÈâÑо¿¡£¼¡Èâ»î¼ì±ê±¾ÓÃÓÚ·ÖÎö×éÖ¯»¯Ñ§ÌØÕ÷¡£6Àý»¼Õß µÄ¼¡Èâ±ê±¾»¹½øÐÐÁ˳¬Î¢½á¹¹Ñо¿¡£ ½á¹û£º×ÊÁÏÏÔʾ£¬ÍíÆÚChD»¼ÕßÍâÖܼ¡ÈâµÄÌÇ·Ö½âÔöÇ¿¶øÑõ»¯ÄÜÁ¦¼õÈõ£¬±íÏÖΪII bÐÍÏËά±ÈÀýÔö¸ß£¬¾ßÓеÍÑÌõ£°·ÏÙàÑßʶþºËÜÕËáÐļ¡»ÆµÝø»îÐÔµÄÏËά±ÈÀýÔö¸ß£¬¾ßÓÐÉîȾɫ a-¸ÊÓÍÁ×ËáÍÑÇâø»îÐÔµÄÏËά±ÈÀýÔö¸ß£¬ÄûÃÊËáºÏ³ÉøµÄˮƽ½µµÍ£»ChD»¼Õß´óÁ¿Ã«Ï¸Ñª¹Ü³öÏÖ±ÕËø»òÕ߹ܱÚÔöºñ µÄÒì³£±íÏÖ¡£¼´Ê¹¹¦ÄÜÕý³£µÄ»¼Õߣ¬³¬Î¢½á¹¹Ñо¿Ò²·¢ÏÖÏËάήËõºÍëϸѪ¹ÜÒì³£¡£Ä³Ð©¼¡ÈâÌØÐÔ (ø»îÐÔ¡¢ÏËάµÄƽ¾ùºá¶ÏÃæ»ýºÍëϸÏÖÏó) ÓëÔ˶¯²ÎÊý (ÎÞÑõãкÍÂö³åÑõ·åÖµ) ÃÜÇÐÏà¹Ø¡£ ½áÂÛ£ºÕâЩ·¢ÏÖ±íÃ÷ÍíÆÚChD»¼Õß¹Ç÷À¼¡µÄÑõ»¯ÄÜÁ¦¼õÈõ²¢×ªÏòÎÞÑõ´úл£¬Í¬Ê±Ò²Ìáʾ¼¡ÈâµÄÒì³£ ÓëÑõÔËËÍÓйأ¬ÕâÖÖÑõÔËË͵ļõÉÙ¿ÉÄܲ¿·ÖÊÇÓÉÓÚ¼¡ÈâµÄ΢Ѫ¹ÜÒì³£µ¼Ö¡£ÕâЩ¸Ä±ä»áÓ°ÏìÑõµÄÉã È¡£¬´Ó¶øÓ°Ï컼ÕßµÄÔ˶¯ÄÍÁ¦¡£ ¹Ø¼ü´Ê£ºÐ¡ (cardiomyopathy); Chagas²¡ (Chagas disease); Ô˶¯ÊÔÑé (exercise test); ·ÎÆøÌå½»»» (pulmonary gas exchange); ¹Ç÷À¼¡ (skeletal muscle)
£¨»Æ´ºÆ¼ Ò룻ʩ»ÀÖРУ£© ¡¾Ó¢ÎÄÔ¼þÇë²ÎÔÄChest, 2004; 125: 1306-1314¡¿
¼¹ËèǰÁÐÏÙËØ²úÉúÓëÐØÀªÇпªÊõºóÍ´¾õµÄ¹ØÏµ ¡¡¡ª¡ª »·¼ÓÑõø- 2µÄ×÷ÓÃ
Connail McCrory, MD; and Desmond Fitzgerald, MD From the Department of Clinical Pharmacology, Royal College of Surgeons in Ireland, Dublin, Ireland. Correspondence to: Desmond Fitzgerald, MD, Department of Clinical Pharmacology, Royal College of Surgeons in Ireland, Dublin, Ireland; e-mail: dfitzgerald@rcsi. ie.
Ä¿µÄ£º¼¹ËèÄÚ²úÉúµÄǰÁÐÏÙËØ (PG) ¿ÉÄÜÔÚÍ´¾õÖÐÆðÖØÒª×÷Óã¬Òò´Ë£¬ÒÖÖÆ¼¹Ëè»·¼ÓÑõø (COX) ºÍPGµÄÐγɿÉÄÜÓë·ÇçÞÌåÀàÏûÑ×Ò© (NSAID) µÄÊõºóÕòÍ´×÷ÓÃÓйء£ÓëÊõºóÌÛÍ´ÓйصÄCOXÒì¹¹ÐÍ (isoform) ÈÔδÇå³þ£¬¹ÊÓбØÒª½«´Ë×÷ΪÑо¿¶ÔÏó¡£ Éè¼Æ£ºÇ°Õ°ÐÔËæ»úä·¨Ñо¿¡£ µØµã£º´óѧ½ÌѧҽԺ¡£ ¶ÔÏó£º30ÀýÐпªÐØ·ÎÒ¶ÇгýÊõºóµÄ»¼Õß¡£ ·½·¨£ºÔÚÒ»Ï·ÅÉè¼ÆµÄÑо¿ÖУ¬»¼ÕßËæ»ú½ÓÊÜCOX-2Ñ¡ÔñÐÔÒÖÖÆ¼ÁÄáÃÀÊæÀû (nimesulide) 100 mg¿Ú·þ£¬Ã¿Ìì2´Î£»»ò·ÇÑ¡ÔñÐÔÒÖÖÆ¼Á²¼Âå·Ò (ibuprofen) 400 mg¿Ú·þ£¬Ã¿Ìì3´Î¡£ÁíÍ⣬»¹ÉèÖÃÒ»×é²»ÓÃNSAIDµÄËæ»ú¶ÔÕÕ×é¡£ÊÕ¼¯ÄÔ¼¹Òº (CSF) ÓÃÓÚ¼ì²âǰÁл·ËصÄÖ÷Òª´úл²úÎï6 -ͪ- PGF1aµÄº¬Á¿¡£COX-1ºÍCOX-2µÄ»îÐÔͨ¹ý²â¶¨È«ÑªÖеÄѪÇåÑªË¨ËØ (TX) B2ºÍÄÚ¶¾ËØÓÕµ¼µÄPGE2µÄ²úÉúÓèÒÔÅжϡ£ ²â¶¨£ºÍ¨¹ýÊÓ¾õÄ£ÄâÆÀ·Ö²âÁ¿Í´¾õ£¬Í¬Ê±Ó¦ÓÃä·¨ÆÀ¼Û¶Ô°¢Æ¬Ààֹʹ¼ÁµÄÐèÒªÁ¿ÒÔ¼°²â¶¨ºôÆø·åÁ÷ Á¿¡£ ½á¹û£º»ùÓÚѪÇåTXB2Ũ¶È£¬ËùÓõÄÄáÃÀÊæÀû¼ÁÁ¿¶ÔCOX-2ÓÐÑ¡ÔñÐÔ¶ø²¼Âå·ÒÔòÎÞÑ¡ÔñÐÔ¡£CSFµÄ 6 -ͪ- PGF1aƽ¾ùŨ¶È´ÓÊõǰµÄ (32¡À4.9) pg/mLÉÏÉýµ½ÊõºóµÄ (127¡À29) pg/mL (P < 0.001)£¬¿Ú·þÄáÃÀÊæÀûÔò¿ÉʹÆäϽµÖÁ (49¡À9.3) pg/mL (P = 0.002 5)£¬¶ø²¼Âå·Ò¶Ô6 -ͪ- PGF1aŨ¶ÈÎÞÓ°Ïì [(122¡À35) pg/mL]¡£ÄáÃÀÊæÀû×黼ÕßÌÛÍ´ÆÀ·Ö (P < 0.001)¡¢Âð·ÈÐèÒªÁ¿ (P = 0.017 5) ÒÔ¼°ºôÆø·åÁ÷Á¿µÄϽµ (P < 0.001) ¾ùÃ÷ÏԽϵ͡£ ½áÂÛ£ºÐØÀªÇпªÊõºó¼¹ËèǰÁÐÏÙËØºÏ³ÉµÄÔö¼Ó¿É±»Ñ¡ÔñÐÔCOX-2ÒÖÖÆ¼ÁËùÒÖÖÆ£¬Õâ±íÃ÷ÓÕµ¼ÐÔCOX- 2¿É½éµ¼ÖÐÊàÐÔPGµÄºÏ³É¡£ÓÉÓÚÄáÃÀÊæÀûµÄʹÓÃÄÜÃ÷ÏÔ¼õÇáÊõºóµÄÍ´¾õ£¬ÌáʾCOX-2ÔÚÌÛÍ´µÄ²ú Éú·½Ãæ¾ßÓÐÖØÒª×÷Óᣠ¹Ø¼ü´Ê£ºÄÔ¼¹Òº (cerebrospinal fluid); »·¼ÓÑõø (cyclooxygenase); »·¼ÓÑõø-2-ÒÖÖÆ (cyclooxygenase-2 inhibition); ·ÇçÞÌåÀàÏûÑ×Ò© (nonsteroidal anti-inflammatory drugs); ÊõºóÌÛÍ´ (postoperative pain)
£¨»Æ´ºÆ¼ Ò룻ʩ»ÀÖРУ£© ¡¾Ó¢ÎÄÔ¼þÇë²ÎÔÄChest, 2004; 125: 1321-1327¡¿
Ó¦Ó÷ÎÁ¿²â¶¨·¨¿ÉÏÔÖøÌá¸ß»ù²ãÒ½ÁÆÖÐCOPDµÄÔçÆÚ·¢ÏÖÂÊ ¡¡¡¡¡ª¡ªDIDASCOÑо¿
Johan Buffels, MD; Jan Degryse, MD, PhD; Jan Heyrman, MD, PhD; and Marc Decramer, MD, PhD From the Departments of General Practice (Drs. Buffels,Degryse, and Heyrman) and Pulmonology (Dr. Decramer), Katholieke Universiteit, Leuven, Belgium. Correspondence to: Johan Buffels, MD, Academisch Centrum voor Huisartsgeneeskunde Kapucijnenvoer 33 Blok J B-3000 Leuven, Belgium; e-mail: johan. buffels@coditel. net
Ä¿µÄ£ºÍ¨¹ýÓëÒ»Ïî¼ò¶ÌÎʾíµ÷²é½á¹ûµÄ±È½Ï£¬ÆÀ¼Û»ù²ãÒ½ÁÆÖÐÓ¦Ó÷ÎÁ¿²â¶¨·¨¶ÔÔçÆÚ·¢ÏÖ COPDµÄ±ØÒªÐÔ¡£ ·½·¨£º¶Ô12 wkÄÚµ½¼Òͥҽʦ (GP) ´¦¿´²¡¡¢ÄêÁä½éÓÚ35 ~ 70Ëê¼äµÄÈËȺ½øÐÐÎʾíµ÷²é£¬ÄÚÈݹØÓÚ×èÈûÐԷμ²²¡ (OLD) µÄÖ¢×´¡£Ñ¡¶¨ËùÓоßÓÐÑôÐÔÖ¢×´Õߣ¬²¢Ëæ»ú³éÑù10%ÎÞÖ¢×´Õß½øÐзÎÁ¿²â ¶¨¡£¹²ÓÐ20Ãû¼Òͥҽʦ²ÎÓë±¾Ñо¿£¬¾ùÅ䱸±ãЯʽ·ÎÁ¿¼Æ£¬²¢ÓèÒÔÅàѵ·Î¹¦ÄܲⶨµÄ²Ù×÷·½·¨ºÍ ½á¹û·ÖÎö¡£ËùÓÐ35 ~ 70ËêµÄ»¼Õß (n=3 408) ¾ù¾µ±Ç°ÊÇ·ñʹÓÃÖ§Æø¹ÜÀ©ÕÅÒ©ÎïµÄɸ²é¡£Ó¦ÓÃÖ§Æø¹ÜÀ©ÕżÁÕß±»Íƶ¨Îª OLD»¼ÕßÑÇ×é (n=250, 7%)£¬ÓèÒÔÌÞ³ý¡£ÆøµÀ×èÈûµÄ¶¨Òåϵ¸ù¾ÝÅ·ÖÞºôÎüлáµÄ±ê×¼¡£ ½á¹û£ºÎʾíµ÷²éµÄÑôÐÔÔ¤²âÄÜÁ¦½ÏµÍ [Ãô¸Ð¶ÈΪ58%£¬ÌØÒì¶ÈΪ78%£¬ËÆÈ»±È (likelihood ratio)Ϊ2.6]¡£ÓÐÖ¢×´×éÖз¢ÏÖ126Àý֮ǰδ·¢ÏÖµÄOLD£»Ïà±ÈÖ®ÏÂÎÞÖ¢×´×é·¢ÏÖÁË 90Àý¡£¾¡¹ÜËùÓõÄÎʾíµ÷²éµÄÒõÐÔÔ¤²âֵΪ95%£¬µ«Èç¹ûûÓÐʹÓ÷ÎÁ¿²â¶¨·¨£¬Ð·¢ÏÖµÄOLD²¡ÀýÖн«ÓÐ42%±»Â©Õï¡£ ½áÂÛ£ºÔÚ»ù²ãÒ½ÁÆÖÐʹÓ÷ÎÁ¿²â¶¨·¨¶ÔÔçÆÚ·¢ÏÖ OLDÊ®·Ö±ØÒª¡£ÆøµÀ×èÈû¼ì²âµÄɸ²éʹȷÕïµÄOLD»¼ÕßÊýÁ¿¼¸ºõÔö¼Ó1±¶¡£ ¹Ø¼ü´Ê£ºÏø´ (asthma); ÂýÐÔ×èÈûÐԷμ²²¡ (COPD); Õï¶Ï (diagnosis); ¼ÒÍ¥Ò½ÁÆ (family practice); ·ÎÁ¿²â¶¨·¨ (spirometry)
£¨ÁõÓ± Ò룻ÁõÖ¾ У£© ¡¾Ó¢ÎÄÔ¼þÇë²ÎÔÄChest, 2004; 125: 1394-1399¡¿
¼¡Î®ËõÐÔ²àË÷Ó²»¯Ö¢Îȶ¨ÆÚ»¼ÕßÓ¦ÓûúеÐÔ·ÎÄÚ´µÆø-ÅÅÆøµÄЧ¹û
Jesus Sancho, MD; Emilio Servera, MD, FCCP; Juan Diaz, RN; and Julio Marin, MD, FCCP From the Department of Respiratory Medicine, Hospital Clinico Universitario, Universitat de Valencia, Valencia, Spain. Correspondence to: Emilio Servera MD, FCCP, Avda Blasco Ibanez 84, E 46021 Valencia, Spain; e-mail: emilio. servera@uv. es
Ä¿µÄ£ºÈ·¶¨ÔÚºÎÖÖÇé¿öÏÂʹÓûúеÐÔ·ÎÄÚ´µÆø- ÅÅÆø (MI-E)£¬¿Éʹ¼¡Î®ËõÐÔÓ²»¯Ö¢ (ALS) ÁÙ´²Îȶ¨ÆÚ»¼Õß´ïµ½ÓÐЧºôÆøÁ÷Á¿ÒÔ½øÐÐÆøµÀÇå³ý ( > 2.7 L/s)¡£ ²ÄÁϺͷ½·¨£ºÁ¬Ðø26Ãû»¼ÓÐALSµÄ²¡È˲ÎÓë±¾Ñо¿£¬ÆäÖÐ15ÈË»¼ÓÐÑÏÖØµÄÑÓË蹦ÄÜÕϰ¡£½èÖú ¿Ú±ÇÃæÕÖ½øÐкôÎüÁ÷ËÙÃè¼Çͼ²â¶¨FVC¡¢FEV1¡¢¿ÈËÔ·åÁ÷Á¿ (PCF)¡¢×î´ó´µÆøÁ¿ (MIC)¡¢×î´ó´µÆøÁ¿MIC²úÉúµÄPCF (PCFMIC) ºÍMI-E²úÉúµÄPCF (PCFMI-E)¡£MI-EËùÊä³öµÄ¹¤×÷ѹÁ¦Îª ¡À3.9 kPa (40 cmH2O)¡£Í¬Ê±²â¶¨¾¿Ú×î´óÎüÆøÑ¹Á¦ (PImax) ¼°×î´óºôÆøÑ¹Á¦ (PEmax)¡£ ½á¹û£ºËäÈ»ÓлòÎÞÑÓË蹦ÄÜÕϰµÄALS²¡ÈË´Ó³öÏÖÖ¢×´µ½»ñµÃÈ·ÕïÖ®¼äµÄʱ¼äÏà½ü£¬µ«Á½×鲡È赀 ·Î¹¦Äܼ°¿ÈËÔÄÜÁ¦µÈ²ÎÊýµÄ²îÒì¾ßÓÐͳ¼ÆÑ§ÒâÒå (P < 0.05) £ºFVCΪ (2.58 ¡À1.24) ¶Ô (1.62 ¡À0.74) L; FEV1Ϊ (2.26 ¡À1.18) ¶Ô (1.54 ¡À0.69) L; PImaxΪ (-9.16¡À4.65) ¶Ô (-0.36¡À2.46) kPa [(-93.45¡À47.47) ¶Ô (-3.64 ¡À25.07) cmH2O]; PemaxΪ (13.76¡À7.44) ¶Ô (6.85¡À3.15) kPa [(140.45 ¡À75.98) ¶Ô (69.93 ¡À32.14) cmH2O]; MICΪ (3.02 ¡À1.22) ¶Ô (1.97 ¡À0.75) L; PCFΪ (5.91 ¡À2.55) ¶Ô (3.42 ¡À1.44) L/s; PCFMICΪ (6.68 ¡À2.71) ¶Ô (4.00 ¡À1.48) L/s; PCFMI-EΪ (4.34 ¡À0.82) ¶Ô (3.35 ¡À0.77) L/s¡£4ÃûºÏ²¢ÑÓË蹦ÄÜÕϰºÍMIC > 1 L»¼ÕßµÄPCFMI-E < 2.7 L/s¡£½ÓÊÜÕß¹¤×÷ÌØÕ÷ (ROC) ÇúÏß·ÖÎö½á¹ûÌáʾPCFMIC ¡Ü 2.7 L/sµÄ»¼ÕßԤʾÆäPCFMI-E < 2.7 L/s£¬ÇÒ¸ÃÇúÏß·ÖÎöÌáʾPCFMIC > 4 L/sʱԤʾ»¼ÕßµÄPCFMICÖµ´óÓÚPCFMI-E¡£ ½áÂÛ£ºMI-E¿ÉʹALSÎȶ¨ÆÚ»¼Õß²úÉúÓÐЧPCFMI-E ( > 2.7 L/s)£¬µ«ÒªÅųýºÏ²¢ÑÓË蹦ÄÜÕϰMIC > 1 L¡¢PCFMIC < 2.7 L/sµÄ»¼Õߣ¬¶ÔÕâÀ໼ÕßʹÓÃMI-E¿ÉÄÜÔÚÅÅÆøÑ»·¹ý³ÌÖÐÒý·¢ÑÏÖØµÄÉϺôÆøµÀ¶¯ ̬Ïݱա£³ýÁ˺ϲ¢¼±ÐÔºôÎüϵͳ¼²²¡Õߣ¬MI-E¶ÔPCFMIC > 4 L/s°éÇá΢ºôÎü¹¦ÄÜÕϰµÄÁÙ´²Îȶ¨ÆÚ»¼ÕßÎÞЧ¡£ ¹Ø¼ü´Ê£º¼¡Î®ËõÐÔ²àË÷Ó²»¯Ö¢ (amyotrophic lateral sclerosis); ¿ÈËÔÄÜÁ¦ (cough capacity); ·Î¹¦ÄܲâÊÔ (lung function test); »úеÐÔ´µÆø-ÅÅÆø (mechanical insufflation-exsufflation); Éñ¾¼¡Èⲡ (neuromuscular disease); ÎÞ´´ÐÔ¸¨ÖúºôÎü (noninvasive respiratory aids); ÎÞ´´Í¨Æø (noninvasive ventilation); ¿ÈËÔ·åÁ÷Á¿ (peak cough flow)
£¨ÁõÓ± Ò룻ÁõÖ¾ У£© ¡¾Ó¢ÎÄÔ¼þÇë²ÎÔÄChest, 2004; 125: 1400-1405¡¿
·ÎÄÚ´µÆø-ÅÅÆøÆ÷ÔÚ¶ùͯÉñ¾¼¡Èâ¼²²¡ºÍºôÎü¹¦ÄÜË¥Èõ»¼ÕßÖеÄÓ¦ÓÃ
Laura J. Miske, MSN; Eileen M. Hickey, CRNP; Susan M. Kolb, CRNP; Daniel J. Weiner, MD, FCCP; and Howard B. Panitch, MD, FCCP From the Departments of Nursing (Mss. Miske, Hickey, and Kolb) and Pediatrics (Drs. Weiner and Panitch), University of Pennsylvania School of Medicine, The Children’s Hospital of Philadelphia, Philadelphia, PA. Correspondence to: Laura J. Miske, MSN, Pulmonary Division, Fifth Floor, Wood Building, Children’s Hospital of Philadelphia,34th St and Civic Center Blvd, Philadelphia, PA 19104; e-mail: miske@email. chop. edu
±³¾°£ºÉñ¾¼¡Èâ¼²²¡ (NMD) µÄ¼¡ÎÞÁ¦¿ÉÒý·¢¿ÈËÔÄÜÁ¦ÊÜË𣬵¼ÖÂÑÏÖØµÄºôÎüϵͳ²¢·¢Ö¢£¬°üÀ¨·Î ²»ÕÅ¡¢·ÎÑס¢Ð¡ÆøµÀ×èÈû¼°ËáÖж¾µÈ¡£»úеÐÔ·ÎÄÚ´µÆø-ÅÅÆøÆ÷ (MI-E) ÏÈÌṩÕýѹ´µÆø£¬Æäºó²úÉúÖð³öÐÔÅÅÆø£¬¿É´Ì¼¤Õý³£¿ÈËÔ¡£³ÉÈË¿ÈËÔÄÜÁ¦ÊÜËð»¼ÕßÓ¦ÓÃMI-Eºó¿ÉÌá¸ß¿ÈËÔÁ÷Á¿¼°ÔöÇ¿ºôÎü µÀÇå³ýÁ¦¡£µ«Ä¿Ç°MI-EÓ¦ÓÃÓÚ¶ùͯ»¼Õߵı¨µÀÓÐÏÞ¡£ Ä¿µÄ£ºÈ·¶¨ÔÚ¶ù¿Æ»¼ÕßÖÐÓ¦ÓÃMI-EµÄ°²È«ÐÔ¡¢ÄÍÊÜÐÔ¼°ÆäЧ¹û¡£ ·½·¨£ºÁÙ´²²¡Àú»Ø¹ËÐÔÑо¿¡£ ¶ÔÏó£ºÔÚ¶ùͯ·Î¼²²¡¼Æ»®ÖÐÖÎÁƵϼNMDºÏ²¢¿ÈËÔÄÜÁ¦ÊÜË𻼶ù62Ãû (ÄÐÐÔ34Ãû) Èë×é±¾Ñо¿£¬ËùÓл¼¶ù¾ù¸øÓèMI-EÖÎÁÆ¡£¿ªÊ¼Ó¦ÓÃMI-EµÄÖÐλÄêÁäΪ11.3Ëê (3¸öÔÂ~ 28.6Ëê)¡£ÆäÁÙ´²Õï¶Ï°üÀ¨£º¼Ù·Ê´óÐͽøÐÐÐÔ¼¡ÓªÑø²»Á¼Ö¢ (17Ãû); ¢ñÐͼ°¢òÐͼ¹Ë輡ÈâήËõ (21Ãû); ¼¡²¡ (12Ãû£©£»ÆäËû·ÇÌØÒìÐÔÉñ¾¼¡Èâ¼²²¡ (12Ãû)¡£29ÈË¾Æø¹ÜÇпª¸øÓè»úÐµÍ¨Æø£¬25ÈËʹÓÃÎÞ´´ÐÔ»úÐµÍ¨Æø¡£ ½á¹û£ºÖÐλÖÎÁÆÊ±¼äÊýΪ13.4¸öÔ (0.5 ~ 45.5¸öÔÂ)¡£1ÃûÓ¤¶ùÔÚÓÃMI-EÖÎÁÆÇ°ËÀÓÚ¼ÒÖУ¬5Ãû»¼¶ù¾Ü¾ø¼ÌÐøÓ¦ÓÃMI-EÖÎÁÆ£¬2Ãû²úÉú²¢·¢Ö¢µ«ÈÔÓÃMI-EÖÎÁÆ£¬4Ãû»¼¶ù¾MI-EÖÎÁƺóÂýÐԷβ»ÕÅ µÃµ½»º½â£¬5Ãû»¼¶ù¼õÉÙÁ˺ϲ¢·ÎÑ׵ķ¢ÉúÂÊ¡£ ½áÂÛ£º¸ÃÑо¿ÖÐ90%»¼¶ùÓ¦ÓÃMI-EºÜ°²È«£¬ÄÍÊÜÐԺã¬ÔÚÔ¤·À·Î²¿²¢·¢Ö¢ÉÏÓÐЧ¡£ ¹Ø¼ü´Ê£ºÆøµÀÇå³ý (airway clearance); ´µÅÅÆøÆ÷ (cofflator); ¼Ù·Ê´óÐͽøÐÐÐÔ¼¡ÓªÑø²»Á¼Ö¢ (duchenne muscular dystrophy); »úеÐÔ´µÆø-ÅÅÆøÆ÷ (mechanical in-exsufflator); Éñ¾¼¡Èâ¼²²¡ (neuromuscular disease); ¶ù¿ÆÑ§ (pediatrics); ¼¹Ë輡ÈâήËõ (spinal muscular atrophy)
£¨ÁõÓ± Ò룻ÁõÖ¾ У£© ¡¾Ó¢ÎÄÔ¼þÇë²ÎÔÄChest, 2004; 125: 1406-1412¡¿
ÔçÆÚ·ÇСϸ°û·Î°©Î»ÓÚÏÂÒ¶Óë·Î°©·ÖÆÚÏòÉϵ÷ÕûµÄÏà¹ØÐÔÑо¿
Ana T. Rocha, MD, MHS; Meg McCormack, PA-C; Gustavo Montana, MD; and Gilbert Schreiber, MD, PhD From the Division of Pulmonary Medicine (Dr. Rocha and Ms. McCormack), Department of Radiation Oncology (Dr. Montana),Duke University Medical Center, Durham, NC; and Division of Pulmonary Medicine (Dr. Schreiber), University of Utah Health Sciences Center, Salt Lake City, UT. Correspondence to: Gilbert Schreiber, MD, PhD, FCCP, Associate Professor of Medicine, University of Utah Health Sciences Center, Division of Pulmonary Medicine, 26 North 1900 East, Salt Lake City, UT 84132-4701; e-mail: Gilbert.Schreiber@hsc. utah. edu
Ä¿µÄ£ºÍ¨¹ý¶ÔÔçÆÚ·ÇСϸ°û·Î°© (NSCLC) »¼ÕßÁÙ´²¼°²¡Àí·ÖÆÚµÄ±È½Ï£¬È·Á¢Óë¼²²¡´íÎó·ÖÆÚÏà¹ØµÄÒòËØ¡£ Éè¼Æ£ºÇ°Õ°ÐÔ¶ÓÁÐÑо¿¡£ µØµã£ºÄ³´óѧ¸½ÊôÍËÎé¾üÈËÒ½ÁÆÖÐÐĵÄ×ÛºÏÐÔÐØ²¿Ö×Áö¿Æ¡£ ¶ÔÏó£ºÒÑÐпªÐØÁܰͽáÇå³ýÊõµÄ109Ãû»¼ÁÙ´²¢ñ/¢òÆÚ NSCLCµÄÄÐÐÔÍËÎé¾üÈË¡£ ·½·¨£º»Ø¹ËÊÕ¼¯×Ô1997Äê9ÔÂÖÁ2002Äê4ÔµĻ¼ÕßÊý¾Ý¡£Ó¦Óà Logistic»Ø¹é·ÖÎö·¨¼ÆËã·ÖÆÚ±ä»¯Ô¤²âÖµµÄ±ÈÖµ±È (OR)¡£ ½á¹û£º¿ªÐØÁܰͽáÇå³ýÊõºó·¢ÏÖ35.8%µÄ»¼Õß (39/109) Ö×Áö·ÖÆÚÓдíÎó¡£³ý1Ãû»¼ÕßÍâ¾ùΪÁÙ´²·ÖÆÚÏòÉϵ÷Õû¡£Î´Òɼ°µÄÁܰͽá×ªÒÆ (NÆÚ) Õ¼·ÖÆÚÏòÉϵ÷Õû»¼ÕßµÄ16.5%£¬Ö×ÁöT·ÖÆÚ¸Ä±äÕßÕ¼·ÖÆÚÏòÉϵ÷Õû»¼ÕßµÄ 13.8%£»2.7%µÄ·ÖÆÚÏòÉϵ÷Õû»¼ÕßÉÏÊöÁ½ÖÖ·ÖÆÚ¶¼Óиı䣬 1.9%µÄ»¼ÕßÒò»ñÕïÖ×Áö×ªÒÆ¶ø·ÖÆÚÏòÉϵ÷Õû¡£¾¡¹Ü×ݸô¾µ¼ì²é½á¹ûΪÒõÐÔ£¬µ«ÈÔÓÐ 8.3%»¼Õß (9/109) ·¢ÏÖÁËÒÔǰδÒɼ°µÄ×ݸôÁܰͽáÔö´ó (²¡Àí·ÖÆÚN2)¡£ËùÓл¼Õß¶¼ÐÐÍêÕûµÄÖ×ÁöÇгýÊõ£¬·¢ÏÖ 8.3% (9/109) µÄ»¼ÕßΪ¼²²¡ÍíÆÚ (¢óB»ò¢ôÆÚ)¡£Ô·¢Ö×Áö¶¨Î»ÓÚ·ÎÏÂÒ¶ÊÇÓëÖ×Áö·ÖÆÚÏòÉϵ÷Õû¾ßÓÐͳ¼ÆÑ§ÏÔÖøÒâÒåµÄΩһÏà¹ØÒò ËØ (ORΪ3.56£¬95%CIΪ1.4 ~ 9.1)¡£¿ØÖÆÁËÖ×ÁöÌå»ýºÍÏÈǰµÄ×Ýëõ¾µ¼ì²éÇé¿ö£¬¿ÉÒÔÏÔÏÖÖ×Áöλ ÖöÔÖ×Áö·ÖÆÚ¾ßÓнϴóµÄÓ°Ïì¡£»¼ÕßµÄÄêÁä¡¢ÎüÑÌÊ·¡¢ÌåÖØ¼õÇáÖµ¡¢Ö×Áö´óС¼°Ö×Áö×é֯ѧËù¼û ¾ùÓë·ÖÆÚÏòÉϵ÷ÕûÎ޹ء£ ½áÂÛ£ºÔçÆÚNSCLC»¼Õß·ÎÏÂÒ¶Ö×Áö¶¨Î»ÓëÊõºóµÄÖ×Áö·ÖÆÚÏòÉϵ÷ÕûÏà¹Ø¡£±¾Ñо¿Ìáʾ¶Ô¶¨Î»ÓÚÏ ҶµÄÖ×ÁöÒªÌØ±ðÓèÒÔÖØÊÓ¡£ ¹Ø¼ü´Ê£º¿çѧ¿Æ½»Á÷ (interdisciplinary communication); ·ÎÖ×Áö (lung neoplasm); ×ݸô¾µ¼ì²é (mediastinoscopy); Ö×Áö·ÖÆÚ (neoplasm staging); ǰհÐÔÑо¿ (prospective studies); ΣÏÕÒòËØ (risk factors); ¶Ï²ãɨÃè (tomography)
£¨ÁõÓ± Ò룻ÁõÖ¾ У£© ¡¾Ó¢ÎÄÔ¼þÇë²ÎÔÄChest, 2004; 125: 1424-1430¡¿
Ó¦ÓÃÈ«ÉíµçÉúÎï×迹¶ÔÐÄÅųöÁ¿ÐÐÁ¬Ðø¡¢ÎÞ´´µÄ¾«È·ÐÔ¼à²â
Gad Cotter, MD; Yaron Moshkovitz, MD; Edo Kaluski, MD; Amram J. Cohen, MD, FCCP; Hilton Miller, MD; Daniel Goor, MD; and Zvi Vered, MD From the Cardiology Department (Drs. Cotter, Kaluski, and Vered), Assaf-Harofeh Medical Center, Zerifin; the Cardiac Surgery Department (Drs. Moshkovitz and Goor), Sackler School of Medicine, Tel Aviv University, Tel Aviv; the Department of Cardiology (Dr. Miller), Sourasky Medical Center, Tel-Aviv; and the Department of Cardiac Surgery (Dr. Miller), the Edith Wolfson Medical Center, Holon, Israel. Correspondence to: Gad Cotter, MD, Cardiology Department,Assaf-Harofeh Medical Center, 70300, Zerifin, Israel; e-mail: cotterg@hotmail. com
Ä¿µÄ£ºÓÉÓÚÊܼì²â¼¼ÊõµÄÏÞÖÆ (¼´ÓÒÐĵ¼¹ÜÊõ)£¬¶ÔÐÄÅųöÁ¿ (CO) µÄ¼ì²â¶à³Ö½Ï±£ÊصÄ̬¶È¡£È»¶ø½ü¼¸ÄêÓб¨µÀÖ¸³ö£¬²â¶¨ÐÄÔಡ»¼Õߣ¬ÓÈÆäÊdzäѪÐÔÐÄÁ¦Ë¥½ß (CHF) »¼ÕßµÄCOÔÚÕï¶Ï¡¢Î£ÏÕ¶È·Ö²ã¼°ÖÆ¶©ÖÎÁÆ·½°¸µÈ·½Ãæ¿ÉÄÜÓмÛÖµ¡£ÎÒÃdz¢ÊÔʹÓÃÒ»ÏîеÄÎÞ´´¡¢³ÖÐøÐÔÈ«ÉíÉúÎï×迹ϵͳ (NICaS; NI Medical; Hod-Hasharon, Israel) À´¼ì²âCO¡£¸ÃÑо¿Ö¼ÔÚÆÀ¼ÛijÐÄÔಡ»¼Õß¶ÓÁÐÖÐÓ¦ÓÃÎÞ´´ÐÔCO¼à²âϵͳ (NICO) µÄÓÐЧÐÔ¡£ Éè¼Æ£ºÇ°Õ°ÐÔ¡¢Ë«Ã¤¡¢¶ÔÕÕÑо¿, ¶ÔNICO¼°ÈÈÏ¡ÊÍCO²â¶¨½øÐбȽϡ£ ¶ÔÏ󣺽«ÈëÑ¡µÄ122Ãû»¼Õß·ÖΪ3×飺Ðĵ¼¹ÜÕïÁÆÖÐ×é (n=40)£¬¹ÚÂöÅÔÂ·ÒÆÖ²Êõǰ¡¢ÊõÖлòÊõºó×é (n=51) ºÍ¼±ÐÔCHF²¡Çé¼ÓÖØÖÎÁÆÖÐ×é (n=31)¡£ ²âÁ¿¼°·½·¨£ºÊ¹ÓÃä·¨ÓÉ2λ²Ù×÷Õß¶ÔËùÓл¼Õß½øÐÐCO²âÁ¿¡£·Ö±ðÓÃÁ½ÖÖ¼¼ÊõÔÚÿһ¸öʱ¼äµã¸÷ ²â¶¨CO 3´Î£¬Ã¿Ò»Ê±¼äµãµÄ²â¶¨½á¹û¶¼¼ÆËãÆ½¾ùÖµ¡£CO²â¶¨Ê±¼äµãΪÐйÚ×´¶¯Âöµ¼¹ÜÊõÖУ¬¹Ú ×´¶¯ÂöÅÔÂ·ÒÆÖ²Êõǰ¡¢ÊõÖС¢Êõºó£¬¼±ÐÔÐÄÁ¦Ë¥½ß»¼ÕßÐÐÀ©Ñª¹ÜÖÎÁÆÖ®Ç°¼°ÖÎÁƹý³ÌÖС£ ½á¹û£º×îºó¹²µÃµ½418¸ö³É¶ÔµÄCO²â¶¨½á¹û¡£NICOºÍÈÈÏ¡ÊÍ·¨²â¶¨µÄÐÄÔàÖ¸ÊýÖµ (CI) µÄÏà¹ØÐÔr=0.886£¬ÆäÆ«ÒнÏС [(0.000 9¡À0.684) L] (x£ ± 2s)£¬¸÷×éÄÚ»¼ÕߵĽá¹ûÒ»Ö¡£µ±CI < 1.5 L/ (min·m2)ʱ£¬ÈÈÏ¡ÊÍ·¨²â¶¨Öµ±ÈNICO·¨¸ß15%£»µ±CI > 3 L/ (min·m2) ʱ,ÈÈÏ¡ÊÍ·¨µÄ²â¶¨Öµ±ÈNICO·¨²â¶¨µÍ5%¡£ÔÚ¹ÚÂöÅÔÂ·ÒÆÖ²ÊõÖм°¼±ÐÔCHFÀ©Ñª¹ÜÖÎÁƹý³ÌÖÐNICO·¨Ò²Äܾ«È·¼à²âCIµÄ±ä»¯¡£ ½áÂÛ£ºNICOÈ«ÉíÉúÎï×迹²â¶¨·¨¿ÉÓ¦ÓÃÓÚ·¶Î§ºÜ¹ãµÄÁÙ´²ÐÄÔಡµÄѪҺ¶¯Á¦Ñ§¼à²â£¬´Ë·½·¨¿É¶Ô CO½øÐо«È·¡¢¿ìËÙ¡¢ÎÞ´´²â¶¨ºÍ×·×Ù¼à²â¡£ ¹Ø¼ü´Ê£ºÐŦÄÜÊÔÑé (cardiac function test); ÐÄÅųöÁ¿ (cardiac output); ³äѪÐÔÐÄÁ¦Ë¥½ß (congestive heart failure)
£¨ÁõÓ± Ò룻ÁõÖ¾ У£© ¡¾Ó¢ÎÄÔ¼þÇë²ÎÔÄChest, 2004; 125: 1431-1440¡¿
¡¡¡ª¡ª Ò»ÏîǰհÐÔÑо¿
Cyril Goulenok, MD; Mehran Monchi, MD; Jean-Daniel Chiche, MD; Jean-Paul Mira, MD; Jean-Francnis Dhainaut, MD, PhD; and Alain Cariou, MD From the Service de Reanimation Medicale (Drs. Goulenok,Chiche, Mira, Dhainaut, and Cariou), Hopital Cochin Port-Royal, Paris, France; and the Service de Reanimation Medicale (Dr. Monchi), Institut Jacques Cartier, Massy, France. Correspondence to: Cyril Goulenok, MD, Service de Reanimation Medicale, Hopital Cochin Port Royal, 27 rue du Faubourg Saint Jacques, 75679 Paris, Cedex 14, France; e-mail: cyril. goulenok@cch. ap-hop-paris. fr
Ä¿µÄ£º³¬ÖصÄICU»¼ÕßËÆºõ¸ü¶àÔ¤ºó²»Á¼£¬ÇÒ·¢ÉúºÏ²¢Ö¢µÄΣÏÕÐÔ¸ü´ó¡£±¾Ñо¿ÎªÒ»ÏîǰհÐÔÑÐ ¾¿£¬ÓÃÀ´ÆÀ¼ÛÕâÀ໼ÕßµÄÌåÖØÖ¸Êý (BMI) ÓëËÀÍöÂÊÖ®¼äµÄ¹ØÏµ¡£ Éè¼Æ£ºÇ°Õ°ÐÔÁÙ´²Ñо¿¡£ µØµã£ºÄ³´óѧ¸½ÊôÒ½ÔºÄÚÓÐ24ÕÅ´²Î»µÄÄÚ¿ÆICU¡£ ·½·¨£ºÑо¿¶ÔÏó°üÀ¨ICUÖÐ1 yÄÚסԺµÄËùÓл¼Õߣ¬ÈëסICU 24 hÄÚËÀÍö»ò³öÔºµÄ»¼ÕßÓèÒÔÌÞ³ý¡£³¬Öص͍ÒåÊÇBMI´óÓÚ±»Ñ¡³öµÄ¸ÃICU»¼ÕßȺÌåBMIµÄµÚ75°Ù·ÖλÊý¡£ËùÊÕ¼¯µÄÆäËûÊý¾ÝΪ»¼Õß µÄÈË¿Úͳ¼ÆÑ§×ÊÁϼ°ÓëICUÓйصÄÊý¾Ý¡£ÓÃMann-Whitney¼ì²â±È½Ï·ÊÅÖ×é¼°·Ç·ÊÅÖ×é¼äµÄÊý×ÖÊý ¾Ý¡£½«µ¥±äÁ¿·ÖÎöËùµÃµÄÓëICUËÀÍöÂÊÏÔÖøÏà¹ØµÄ±äÁ¿Óöà±äÁ¿Logistic»Ø¹éÄ£ÐͽøÐзÖÎö£¬ÒԲ⠶¨¶ÀÁ¢µÄÔ¤²âÖ¸±ê¡£ ½á¹û£º¹²ÓÐ813Ãû»¼ÕßÈë×é±¾Ñо¿¡£BMIµÄ×î´ó4·ÖλֵΪ27¡£ÒÔ¸ÃÖµ½«»¼Õß·ÖΪ·ÊÅÖ×é (n=215) ºÍ·Ç·ÊÅÖ×é (n=598)¡£Á½×黼Õß¾ßÓÐÏÔÖøÐÔ²îÒìµÄÖ¸±êΪ£ºÄêÁä¡¢ÔÚICUסԺµÄʱ¼ä¡¢¼ò»¯¼±ÐÔ ÉúÀíÆÀ·Ö (SAPS) ¢ò¼°ICUËÀÍöÂÊ¡£·ÊÅÖ»¼ÕßµÄËÀÍöÂÊÏÔÖø¸ßÓÚÓÉSAPS¢òµÃµ½µÄÔ¤¼ÆÖµ (32% ¶Ô 18%£¬P=0.001)¡£ÔºÄÚ¸ÐȾ·¢ÉúƵÂÊ»ò»úÐµÍ¨ÆøÊ±¼ä¾ÍICU»¼ÕßËÀÍöÂʶøÑÔ£¬Ã»ÓÐÏÔÖø²îÒ졣ͨ ¹ý¶à±äÁ¿·ÖÎöµÃµ½ËÀÍöÂʵÄÔ¤²âÒòËØÎªSAPS¢ò (P < 0.000 1) ¼°BMI > 27 (P < 0.01)¡£ ½áÂÛ£º¸ÃÑо¿µÚÒ»¸öÌá³ö¸ßBMIÖµÊÇICU»¼ÕßËÀÍöÂÊÔ¤²âÒò×ÓµÄǰհÐÔÑо¿¡£µ±½ñʹÓõÄÔ¤²âICU »¼ÕßËÀÍöÂÊµÄÆÀ·Öϵͳ²»°üÀ¨BMI»ò·ÊÅÖ£¬Òò´Ë£¬Õâ¿ÉÄܵ͹À·ÊÅÖÈËȺËù´æÔڵķçÏÕ¡£ ¹Ø¼ü´Ê£ºÌåÖØÖ¸Êý (body mass index); Î£ÖØ¼²²¡ (critical illness); ËÀÍöÂÊ (mortality); ·ÊÅÖ (obesity); ³¬ÖØ (overweight); Ô¤ºóÖ¸±ê (prognostic index)
£¨ÁõÓ± Ò룻ÁõÖ¾ У£© ¡¾Ó¢ÎÄÔ¼þÇë²ÎÔÄChest, 2004; 125: 1441-1445¡¿
±ÇÑʾµ¼ì²é¶Ô¶ùͯ´ÃùµÄÁÙ´²ÒâÒå
Brian P. O'Sullivan, MD, FCCP; Lenna Finger, MD; and Robert G. Zwerdling, MD From the Department of Pediatrics, University of Massachusetts Medical School, UMass Memorial Health Care, Worcester, MA. Dr. Finger is currently at Baystate Medical Center, Springfield, MA. Correspondence to: Brian P. O'Sullivan, Department of Pediatrics,University of Massachusetts Medical School, UMass Memorial Health Care, 55 Lake Ave, North, Worcester, MA 01655; e-mail: osullivb@ummhc. org
Ä¿µÄ£ºÆÀ¼Û±ÇÑʾµ¶ø²»Êdz£¹æÏËÎ¬Ö§Æø¹Ü¾µ¼ì²é¶ÔºôÎü¿Æ¾ÍÕïµÄ¡¢°éÓзÇÌØÒìÐÔ´ÃùÖ¢×´¶ùͯµÄÁÙ ´²ÒâÒå¡£ Éè¼Æ£º»Ø¹ËÐÔµ÷²é£¬²éÔĺͷÖÎö1990Äê1ÔÂ1ÈÕÖÁ 1999Äê12ÔÂ31ÈÕ¶ùͯ±ÇÑʾµ¼ì²éµÄÔʼ¼Ç¼£¬Í¨¹ýÃÅÕï»òÖ±½ÓÓ뻼¶ù¼Ò³¤»ò¼ÒͥҽʦÁªÏµÈ¡µÃËæ·Ã×ÊÁÏ¡£ µØµã£ºÑ§Ð£ºÍ»ù²ãÒ½ÁƵ¥Î»¡£ ½á¹û£º81Ãû°éÓдÃùÖ¢×´µÄ¶ùͯ¾±ÇÑʾµ¼ì²é±»È·ÕïÎªÐØÇ»Íâ¼²²¡¡£ÆäÖÐ 1Ãû¶ùͯÒòΪ²»Í¬µÄÖ¢×´ÔÚ¼¸ÄêÖÐ×÷ÁËÁ½´Î¼ì²é£¬¹ÊÑо¿ÈËȺ×ܹ²×÷ÁË 82´Î±ÇÑʾµ¼ì²é¡£3/4±»¼ì²éµÄ¶ùͯÖ÷ÒªÖ÷ËßÊÇ´Ãù£¬ÓÐÒ»°ëµÄ¶ùͯ»¼ºíÈí¹ÇÈí»¯Ö¢¡£¶Ô 81¸ö¶ùͯÖеÄ75È˽øÐÐÁ˳¤ÆÚËæ·Ã (ÖÐÎ»Ëæ·ÃÆÚ6 y£¬1~13 y)£¬½á¹ûûÓз¢ÏÖÓ¤Ó×¶ùʱÆÚ¾±ÇÑʾµ¼ì²é©ÕïµÄÆøµÀ²¡±äµÄ·¢ÉúÓë·¢Õ¹¡£ ½áÂÛ£ºÖ»ÒªÄܽøÐÐÓÐЧµÄËæ·Ã£¬±ÇÑʾµ¼ì²é£¨²»Ê¹ÓÃÏÂÆøµÀÄÚ¿ú¾µ£©Äܰ²È«µØ¶Ô°éÓдÃùÖ¢×´µÄ Ó¤Ó×¶ù×÷³öÁÙ´²ÆÀ¼Û¡£ ¹Ø¼ü´Ê£ºÖ§Æø¹Ü¾µ¼ì²é (bronchoscopy); ºíÈí¹ÇÈí»¯Ö¢ (laryngomalacia); ¶ù¿ÆÑ§ (pediatrics); ´Ãù (stridor); ÉÏÆøµÀ (upper airway)
£¨¶Àöϼ Ò룻³Â±¦Ôª У£© ¡¾Ó¢ÎÄÔ¼þÇë²ÎÔÄChest, 2004; 125: 1265-1269¡¿
ͬʱӦÓÿ¹ÒÖÓôºÍ¿¹¸ßѪѹҩÎïÔö¼Ó×èÈûÐÔ˯ÃߺôÎüÔÝÍ£·¢ÉúµÄ¿ÉÄÜÐÔ
Robert J. Farney, MD, FCCP; Alejandra Lugo, BA; Robert L. Jensen, PhD; James M. Walker, PhD; and Tom V. Cloward, MD, FCCP From the Intermountain Sleep Disorders Center (Drs. Farney, Walker, and Cloward), Medical Informatics (Ms. Lugo), and Pulmonary Division, Department of Medicine (Dr. Jensen), LDS Hospital, Salt Lake City, UT. Correspondence to: Robert J. Farney, MD, FCCP, Intermountain Sleep Disorders Center, LDS Hospital, 325 Eighth Ave and C St, Salt Lake City, UT 84143; e-mail: rjfmd@msn. com
±³¾°£ºÔÚ»ù²ãÃÅÕԷ¢ÐÔ¸ßѪѹͬʱºÏ²¢ÒÖÓôµÄÖ¢×´ (ÈçĪÃûµÄÆ£ÀÍ»òÀÍÀÛ) ÊǺܳ£¼ûµÄ¡£ÎÞÂÛÔõÑù×Ðϸ¼ì²é£¬¶¼ÄÑÒÔ·¢ÏÖÃ÷È·µÄ¼²²¡£¬µ«×èÈûÐÔ˯ÃߺôÎüÔÝÍ£ (OSA) ³£Í¬Ê±°éÓиßѪѹ»òÒÖÓôÖ¢×´¡£Ñо¿Ö¼ÔÚÑé֤ͬʱӦÓÿ¹¸ßѪѹºÍ¿¹ÒÖÓôÒ©ÎïÔö¼ÓOSA·¢ÉúµÄ¿ÉÄÜÐÔ¡£ ·½·¨£º·ÖÎö¼ÆËã»ú´æ´¢µÄ212 972Ãû»¼ÕßµÄ×ÊÁÏ£¬ËûÃÇͬʱ½ÓÊÜ¿¹¸ßѪѹºÍ¿¹ÒÖÓôÒ©ÎïÖÎÁÆ£¬·ûºÏ ¹ú¼Ê¼²²¡·ÖÀàµÚ9°æOSA±àÂë¡£¼ÆËãÁ˾¹ýÐÔ±ðºÍÄêÁäУÕýµÄ»¼²¡ÂÊ¡¢»¼²¡±ÈÖµ±È (POR) ¼°¿ÉÐÅÇø¼ä (CI)¡£ ½á¹û£ºÔÚ20 ~ 39Ëê¡¢40 ~ 59ËêºÍ ¡Ý 60Ëê3×黼ÕßÖУ¬OSA µÄ»¼²¡ÂÊÄÐÐÔ·Ö±ðΪ0.8%¡¢2.8%ºÍ3.2%£¬Å®ÐÔ·Ö±ðΪ0.4%¡¢1.4%ºÍ 1.8% ¡£ÓëÏàÓ¦ÄêÁä¡¢ÐÔ±ðµÄûÓнÓÊܸßѪѹºÍÒÖÓôÖÎÁƵϼÕ߱Ƚϣ¬¸÷ÄêÁä×é×î¸ßµÄPORÖµ³öÏÖÓÚͬʱ½ÓÊÜÒÔÉÏÁ½ÖÖÖÎÁƵϼÕߣºÄÐÐÔ·Ö±ðΪ18.30 (95%CIΪ10.69 ~ 25.66)¡¢5.72 (95% CIΪ4.10 ~ 6.70) ºÍ 4.47 (95% CIΪ2.45 ~ 7.01)£¬Å®ÐÔ·Ö±ðΪ17.43 (95% CIΪ9.54 ~ 28.67)¡¢7.29 (95% CIΪ5.20 ~ 9.29) ºÍ2.72 (95% CIΪ1.48 ~ 4.73)¡£ ½áÂÛ£ºÎÞÂÛ·þÓÿ¹¸ßѪѹҩ»¹ÊÇ¿¹ÒÖÓôÒ©£¬»¼Õß±»Õï¶ÏΪOSAµÄ¿ÉÄÜÐÔ¾ùÔö¼Ó¡£Í¬Ê±·þÓÃÁ½ÖÖÒ© ÎïµÄÖÐÇàÄ껼Õß»¼OSAµÄ¿ÉÄÜÐÔ×î¸ß¡£Èκλ¼ÓиßѪѹºÍÒÖÓôÖ¢»òͬʱ·þÓÿ¹¸ßѪѹºÍ¿¹ÒÖÓôÒ©Îï µÄ»¼Õß¶¼Ó¦¸Ã¿¼ÂÇÓпÉÄÜÊÇOSA»¼Õß¡£ ¹Ø¼ü´Ê£ºÒÖÓôÖ¢ (depression); Æ£ÀÍ (fatigue); ¸ßѪѹ (hypertension); ×èÈûÐÔ˯ÃߺôÎüÔÝÍ£×ÛºÏÕ÷ (obstructive sleep apnea syndrome); »¼²¡ÂÊ (prevalence); »¼²¡±ÈÖµ±È (prevalence odds ratio)
£¨¶Àöϼ Ò룻³Â±¦Ôª У£© ¡¾Ó¢ÎÄÔ¼þÇë²ÎÔÄChest, 2004; 125: 1279-1285¡¿
2ÐÍÌÇÄò²¡»¼ÕßÔ˶¯ÆøÌå½»»»¹¦Äܵı仯Óë΢°×µ°°×ÄòÏà¹Ø
Arthur Chun-Wing Lau, FHKAM; Matthew Kwok-Wing Lo, FRCP; Godwin Tat-Chi Leung, FHKAM; Frankie Pak-Tat Choi, FHKAM; Loretta Yin-Chun Yam, FRCP, FCCP; and Karlman Wasserman, MD, FCCP From the Department of Medicine (Drs. Lau, Lo, Leung, and Yam) and Department of Nuclear Medicine (Dr. Choi), Pamela Youde Nethersole Eastern Hospital, Hong Kong, China; andDivision of Respiratory and Critical Care Physiology and Medicine (Dr. Wasserman), Department of Medicine, Harbor-UCLA Medical Center, Torrance, CA. Correspondence to: Arthur Chun-Wing Lau, FHKAM, Division of Respiratory and Critical Care Medicine, Department of Medicine, Pamela Youde Nethersole Eastern Hospital, 3 Lok Man Rd, Hong Kong SAR, PRC; e-mail: drcwlau@hkstar. com
Ä¿µÄ£ºÎ¢°×µ°°×ÄòÊÇÌÇÄò²¡»¼ÕßÐÄѪ¹Ü¼²²¡µÄΣÏÕÒò×Ó¡£Ñо¿¼ÙÉè2ÐÍÌÇÄò²¡»¼ÕßµÄ΢°×µ°°×ÄòÓë Ô˶¯Ðķι¦ÄÜËðÉËÓйأ¬¶øÇÒËðÉ˵ÄÑÏÖØ³Ì¶ÈÓë΢°×µ°°×Äò³Ì¶ÈÏà¹Ø¡£ Éè¼Æ£º¶ÔÊÜÊÔÕß½øÐÐ̤³µÊ½Ðķι¦ÄÜÔ˶¯ÊÔÑ飬ÿ20ÀýΪһ×飬°´ÏÂÁÐÌõ¼þ·ÖΪ3×飺(1) 2ÐÍÌÇÄò²¡Äòµ°°×Õý³£µÄ»¼Õß [Äòµ°°×Åųý (UAE) < 30 mg/d]; (2) 2ÐÍÌÇÄò²¡»¼ÕßÓÐ΢°×µ°°×Äò (UAE 30 ~ 300 mg/d); (3) Õý³£¶ÔÕÕ×é¡£ ·½·¨Óë½á¹û£ºÎ¢°×µ°°×ÄòÌÇÄò²¡×黼ÕßµÄÑõºÄÁ¿ ( ½áÂÛ£ºÔ˶¯Ê±Î¢°×µ°°×Äò×黼Õß±íÏÖΪÑõÆøµÄÔËÊäºÍÆøÌå½»»»¹¦ÄܼõÈõ£¬ÕâЩ¸Ä±ä¼Ì·¢ÓÚ·Î΢Ѫ¹Ü ²¡±äºÍÐäÖʲ¡±ä¡£ÓëÉöÔàµÄ²¡±äÏàͬ£¬Ã«Ï¸Ñª¹Üµ°°×ͨ͸ÐÔµÄÔö¼Ó¿ÉÒÔ·¢ÉúÔÚÐļ¡£¬µ¼ÖÂËðÉË ÐÔµÄÐļ¡Ö×ÕͺÍÊæÕŹ¦Äܲ»È«¡£ ¹Ø¼ü´Ê£ºÔ˶¯ (exercise); ÆøÌå½»»» (gas exchange); ΢Á¿µ°°×Äò (microalbuminuria); 2ÐÍÌÇÄò²¡ (type 2 diabetes)
£¨¶Àöϼ Ò룻³Â±¦Ôª У£© ¡¾Ó¢ÎÄÔ¼þÇë²ÎÔÄChest, 2004; 125: 1292-1298¡¿
³¤ÆÚ¼ä¶Ï¾²Âö¶à°Í·Ó¶¡°·ÁªºÏ¿Ú·þ°·µâͪ¶ÔÍíÆÚÐÄÁ¦ Ë¥½ß»¼ÕßÁÆÐ§¹Û²ì ¡ª¡ª Ò»ÏîËæ»ú˫äÑо¿
John N. Nanas, MD; Eleftheria P. Tsagalou, MD; John Kanakakis, MD; Serafim N. Nanas, MD; John V. Terrovitis, MD; Thomas Moon, PhD; and Maria I. Anastasiou-Nana, MD From the University of Athens School of Medicine, Department of Clinical Therapeutics, "Alexandra"Hospital, Athens, Greece. Correspondence to: John N. Nanas, MD, Makedonias 24, 104 33 Athens, Greece; e-mail: jnanas@ath. forthnet. gr
Ä¿µÄ£º¹Û²ì³¤ÆÚ¼ä¶Ï¾²ÂöÊäÈë¶à°Í·Ó¶¡°·ÁªºÏ¿Ú·þ°·µâͪÖÎÁƳäѪÐÔÐÄÁ¦Ë¥½ß (CHF) µÄÁÆÐ§¡£ Éè¼Æ£ºÇ°Õ°¡¢Ëæ»ú¡¢Ë«Ã¤¡¢ÓжÔÕÕ×éµÄÁÙ´²Ñо¿¡£ µØµã£º´óѧҽԺÐÄÁ¦Ë¥½ßÒ½ÁÆÖÐÐÄ (סԺÓëÃÅÕï)¡£ ·½·¨£º30ÀýÍíÆÚÄÑÖÎÐÔ³äѪÐÔÐÄÁ¦Ë¥½ß»¼Õߣ¬ÔÚÍ£Ö¹³õʼ 72 h¶à°Í·Ó¶¡°·ÖÎÁƺó£¬ÒÔËæ»ú¡¢Ë«Ã¤·¨·ÖΪÁ½×é¡£µÚÒ»×é14Àý»¼Õß¾²ÂöÊäÈ밲ο¼Á£¬µÚ¶þ×é16Àý»¼ÕßÊäÈë¶à°Í·Ó¶¡°·10 mg/(kg·min)£¬ÊäÈë¾ù³ÖÐø8 h£¬Ã¿14Ìì1´Î¡£ËùÓл¼Õß¾ù½ÓÊܱê×¼µÄÖÎÁÆ£¬²¢ÇÒÔÚËæ»ú·Ö×éǰÖÁÉÙ 14 d¿ªÊ¼¿Ú·þ°·µâͪ400 mg/d¡£ ²âÁ¿Óë½á¹û£ºKaplan-Meier Éú´æ·ÖÎöÏÔʾ£ºÁªºÏÓ¦Óöà°Í·Ó¶¡°·ºÍ°·µâͪÖÎÁÆ×éÓ밲ο¼Á¼Ó°·µâͪ ×éÏà±È£¬¸÷ÖÖËÀÒòµÄΣÏÕ¶ÈϽµÁË60% (·çÏÕ±ÈΪ0.403£¬95%CIΪ0.164 ~ 0.992£¬P=0.048)¡£¶à°Í·Ó¶¡°·ÖÎÁÆ×é1¡¢2 yµÄÉú´æÂÊ·Ö±ðΪ69%ºÍ44%£¬ÏàÓ¦°²Î¿¼Á¶ÔÕÕ×éΪ28%ºÍ21% (P < 0.05)¡£ µÚ¶þ×éÓëµÚÒ»×éµÄÖÐλÊýÉú´æÊ±¼ä·Ö±ðΪ574ºÍ144 d¡£ÔÚµÚ6¸öÔÂʱ£¬Á½×é´æ»î»¼ÕßµÄÐŦÄÜNY·Ö¼¶¾ùµÃµ½Ã÷ÏÔ¸ÄÉÆ¡£ ½áÂÛ£º¶ÔÓÚ³£¹æÖÎÁÆÊ§°ÜµÄÍç¹ÌÐÔ³äѪÐÔÐÄÁ¦Ë¥½ß»¼Õߣ¬ÔÚ³£¹æÒ©ÎïÖÎÁƵĻù´¡ÉϼÓÓó¤ÆÚ¼ä¶Ï¾² Âö¶à°Í·Ó¶¡°·ÁªºÏ°·µâͪÖÎÁÆ¿ÉÒÔÌá¸ßÉú´æÂÊ¡£ ¹Ø¼ü´Ê£ºÐÄÁ¦Ë¥½ß (heart failure); Ó°Ï켡ÊÕËõÁ¦ÒòËØ (inotropic agents); Éú´æ (survival)
£¨¶Àöϼ Ò룻³Â±¦Ôª У£© ¡¾Ó¢ÎÄÔ¼þÇë²ÎÔÄChest, 2004; 125: 1198-1204¡¿
ÉçÇøÐ£ËÀÈËȺ³¬ÖØ»¼²¡Âʼ°Ôö³¤Ç÷ÊÆ¶ÔÔ¤ºóµÄÓ°Ïì
Francisco Lopez-Jimenez, MD, MSc; Steven J. Jacobsen, MD, PhD; Guy S. Reeder, MD; Susan A. Weston, MS; Ryan A. Meverden, BS; and Veronique L. Roger, MD, MPH From the Division of Cardiovascular Diseases and Internal Medicine (Drs. Lopez-Jimenez, Reeder, and Roger), Division of Clinical Epidemiology (Dr. Jacobsen), and the Division of Biostatistics (Ms. Weston and Mr. Meverden), Mayo Clinic and Mayo Foundation, Rochester, MN. Correspondence to: Veronique L. Roger, MD, MPH, Division of Cardiovascular Diseases and Internal Medicine, Mayo Clinic,200 First St SW, Rochester, MN 55905; e-mail: oger. veronique@mayo. edu
Ä¿µÄ£ºÌ½ÌÖÐ£ËÀ (MI) ÈËȺÖг¬ÖØÓë·ÊÅֵϼ²¡Ç÷ÊÆ£¬ÆÀ¹ÀÌåÖØÓëMIÔ¤ºóµÄ¹ØÏµ¡£ Éè¼Æ£ºÌض¨ÈËȺµÄÑо¿¡£ ·½·¨£ºÑ¡È¡1979ÖÁ1998ÄêÃ÷ÄáËÕ´ïÖÝ OlmstedÏØ¾Í³Ò»±ê׼ȷÈϵÄMI»¼Õß¡£´ÓÉçÇøÒ½ÁƵµ°¸ÖлñµÃ»¼ÕßµÄÁÙ´²ÌØÕ÷¼°Ô¤ºóµÄ×ÊÁÏ£¬¶Ô»¼Õß³¬Öصϼ²¡ÂʺÍÔö³¤Ç÷ÊÆ¼°ÆäÓëÔ¤ºóµÄ¹ØÏµ½øÐзÖÎö¡£ ½á¹û£ºÔÚ2 277ÀýMI»¼ÕßÖУ¬³¬ÖØ»ò·ÊÅÖÕßÕ¼64%¡£³¬ÖØÓë·ÊÅֵϼ²¡ÂÊ´Ó1979£1983Äê¼äµÄ 58%Ôö³¤ÖÁ1994£ 1998Äê¼äµÄ72% (P<0.001)£¬¶øÇÒÖØ¶È·ÊÅÖ (ÌåÖØÖ¸Êý ¡Ý 40) µÄ»¼²¡ÂÊ´Ó0.6%Ôö¼ÓÖÁ4.4%¡£³¬ÖغͷÊÅÖ»¼ÕßÓëÌåÖØÕý³£ÕßÏà±È£¬¸üÒ×»¼ÌÇÄò²¡¡¢¸ßѪѹ¡¢¼Ò×åÐÔ¹ÚÐIJ¡ºÍ¸ß֬Ѫ Ö¢£¬¶ø»¼ÁíÍâһЩ¼²²¡ (×èÈûÐԷβ¡¡¢ÐÄÁ¦Ë¥½ß¡¢°©Ö¢¡¢Éö¹¦ÄÜË¥½ßºÍÄÔ×äÖÐ) µÄ¿ÉÄÜÐÔ½ÏµÍ (ËùÓÐP<0.05)¡£¾¹ý¶ÔÄêÁäºÍÆäËûÓ°ÏìÒòËØÐ£Õýºó£¬³¬ÖغͷÊÅÖ»¼ÕßÓëÌåÖØÕý³£ÕßÏà±È£¬¾ßÓÐ½ÏµÍµÄ ËÀÍöÂÊ (³¬ÖØÕß·çÏÕ±ÈRRΪ0.84, 95%CIΪ0.73 ~ 0.96£»·ÊÅÖÕßRRΪ0.85, 95%CIΪ0.72 ~ 1.02)£¬·¢ÉúÐÄÔàʼþµÄΣÏճ̶ÈÏà½ü¡£ ½áÂÛ£ºMI»¼ÕßÖг¬ÖØÓë·ÊÅֵϼ²¡Âʸߣ¬ÓÐËæ×Åʱ¼äÔö¼ÓµÄÇ÷ÊÆ¡£¾¡¹Ü·ÊÅÖ»¼Õß¾ßÓÐ½Ï¸ßµÄÆäËû ÐÄѪ¹Ü·¢²¡Î£ÏÕÒòËØ£¬¶øÊµ¼ÊÉÏÕâЩ»¼ÕßµÄÔ¤ºó²¢²»±ÈÕý³£ÌåÖØÕ߲ÐèÒª¶ÔÌåÖØÓë MIÔ¤ºó¼ä·´³£µÄ¹ØÏµ½øÐнøÒ»²½µÄÑо¿¡£ ¹Ø¼ü´Ê£ºÌåÖØÖ¸Êý (body mass index); Ð£ËÀ (myocardial infarction); ·ÊÅÖ (obesity); Ô¤ºó (outcomes); »¼²¡ÂÊ (prevalence)
£¨¶Àöϼ Ò룻³Â±¦Ôª У£© ¡¾Ó¢ÎÄÔ¼þÇë²ÎÔÄChest, 2004; 125: 1205-1212¡¿
Íâ¿ÆÖÎÁƶñÐÔÖ×ÁöºÏ²¢Ðİü»ýÒº»¼ÕßµÄÔ¤ºóÒòËØ
Carey A. Cullinane, MD; I. Benjamin Paz, MD; David Smith, PhD; Nora Carter, MA; and Frederic W. Grannis, Jr, MD, FCCP From the Section of Thoracic and Vascular Surgery (Dr. Grannis), Division of General Oncologic Surgery (Drs. Cullinane and Paz), and Department of Biostatistics (Dr. Smith and Ms. Carter), City of Hope National Medical Center, Los Angeles, CA. Correspondence to: Frederic W. Grannis, Jr, MD, FCCP, Department of Surgery, 1500 East Duarte Road, Duarte, CA 91010; e-mail: fgrannis@coh. org
±³¾°£º°©Ö¢»¼Õß³öÏÖÐİü»ýҺΪһ¶ÀÌØµÄÖÎÁÆÎÊÌâ¡£¾¡¹Ü¿ÉÒÔ²ÉÓöàÖÖÊÖÊõºÍ·ÇÊÖÊõ·½·¨¶ÔÐİü»ý Òº½øÐÐÒýÁ÷£¬Íâ¿ÆÐİü¿ª´°ÊõÈÔ²»Ê§Îª³¤ÆÚÒýÁ÷µÄ±ê×¼·½·¨¡£Ñ¡ÔñÊʺÏÓÚÊÖÊõ´¦ÀíµÄ»¼Õß²¢²»ÈÝ Òס£ÔÚ±¾Ñо¿ÖУ¬ÎªÁËÈ·¶¨°©Ö¢ÀàÐÍ¡¢Ðİü»ýÒº»ò×éÖ¯±ê±¾ÖеĶñÐÔϸ°ûÇé¿ö¡¢ÒÔ¼°Íâ¿Æ·½·¨¶Ô »¼ÕßÐİü»ýÒº¸´·¢ÂÊ»òÉú´æÆÚµÄÓ°Ï죬ÎÒÃǻع˷ÖÎöÁË×Ô1990 Äê1ÔÂ1ÈÕÖÁ2001Äê7ÔÂ1ÈÕÔÚHopeÊйú¼ÒҽѧÖÐÐÄÁ¬ÐøÊÕÖ뵀 63Àý¶ñÐÔÖ×Áö»¼ÕßµÄÔ¤ºó£¬ËûÃÇÓÉÓÚ³öÏÖÖ¢×´ÐÔÐİü»ýÒº½ÓÊÜÁËÍâ¿ÆÐÄ °ü¿ª´°ÊõÖÎÁÆ¡£ ·½·¨£º¸Ã¶ÓÁаüÀ¨15Àý·ÇСϸ°û·Î°© (NSCLC) »¼Õß¡¢22ÀýÈéÏÙ°©»¼Õß¡¢17ÀýѪҺ¶ñÐÔ¼²²¡»¼Õß¡¢9ÀýÆäËûʵÌåÐÔÖ×Áö»¼Õß¡£¼Ç¼Ïà¹ØµÄÁÙ´²×ÊÁÏ¡¢ÊµÑéÊÒ¼ì²é½á¹û¡¢×¡Ôº¾¹ýºÍÔ¤ºóÒÔ¼°³¤ÆÚËæ·Ã ½á¹ûµÈ×ÊÁÏ¡£»¼Õß¾ù×·×Ùµ½×îºóÒ»´ÎÁÙ´²Ëæ·Ã»òÕßËÀÍö¡£Ó¦Óõ¥±äÁ¿Éú´æ·ÖÎö·¨È·¶¨Ó°ÏìÔ¤ºóµÄÖØ ÒªÁÙ´²ÒòËØ¡£ ½á¹û£ºÑо¿×éµÄËæ·Ãʱ¼äÖÐλÊýΪ6.6¸öÔ£¬´æ»îÖÁ×îºóÒ»´ÎËæ·ÃµÄ»¼ÕßµÄËæ·ÃÖÐλʱ¼äΪ 8.3¸öÔ¡£·Î°©¡¢ÈéÏÙ°©¡¢ÑªÒººÍÆäËûʵÌå¶ñÐÔÖ×Áö»¼ÕßµÄÖÐλ´æ»îʱ¼ä·Ö±ðΪ 3.2¡¢8.8¡¢17ºÍ16.4¸öÔ¡£ÊõǰÓëÉú´æÂʳʸºÏà¹ØµÄÒòËØ°üÀ¨Õï¶ÏΪ NSCLC (P = 0.001 4)¡¢ÐØÇ»»ýÒºµÄ´æÔÚ (P = 0.003)¡¢ÑôÐÔ²¡Àíѧ (P = 0.02) »òϸ°ûѧ·¢ÏÖ (P = 0.02)¡£ ½áÂÛ£ºÊÖÊõ·½·¨¶ÔÐİüÒýÁ÷ÊÇÓÐЧµÄ (ʧ°ÜÂÊ < 5%)£¬²¢ÇÒΪ»¼ÕßÌṩÁ˺óÐøÖÎÁƵĻú»á£¬Äܹ»¼õÇỼÕߵĺôÎüÀ§ÄÑ¡¢¸ÄÉÆÉú»îÖÊÁ¿ºÍÌá¸ßÉú´æÂÊ¡£ ¹Ø¼ü´Ê£ºÐİüÌîÈû (cardiac tamponade); ¶ñÐÔ¼²²¡ (malignancy); ¹ÃÏ¢ÊÖÊõ (palliative surgery); Ðİü»ýÒº (pericardial effusion); Ðİü¿ª´° (pericardial window)
£¨»Æ´ºÆ¼ Ò룻ʩ»ÀÖРУ£© ¡¾Ó¢ÎÄÔ¼þÇë²ÎÔÄChest, 2004; 125: 1328-1334¡¿
ÎüÑÌ»·¾³¿ÉÄܵ¼Ö½¡¿µÄÐÐÔÇàÉÙÄêÔçÆÚ·ÎËðº¦
Maurizio Rizzi, MD; Margherita Sergi, MD; Arnaldo Andreoli, MD; Marica Pecis, MD; Claudio Bruschi, MD; and Francesco Fanfulla, MD From the Respiratory Function Laboratory (Drs. Rizzi, Sergi, Andreoli, and Pecis), Ospedale Sacco, Milano; and Fondazione Salvatore Maugeri IRCCS (Drs. Bruschi and Fanfulla), Istituto Scientifico di Montescano, Montescano, Italy. Correspondence to: Francesco Fanfulla, MD, Laboratorio di Fisiopatologia Respiratoria, Fondazione S. Maugeri Centro, Medico di Riabilitazione di Montescano, 27040 Montescanp (PV), Italy; e-mail: ffanfulla@fsm. it
Ä¿µÄ£º¶ùͯʱÆÚ±©Â¶ÓÚÎüÑÌ»·¾³ (ETS) »á¶Ô¶¯Ì¬·Î¹¦ÄÜÖ¸±ê²úÉú²»Á¼Ó°Ï죬ÕâÊÇÔçÄêÉú»î (°üÀ¨¹¬ÄÚ) ¼°ºóÀ´±©Â¶ÓÚ¸¸Ä¸ÎüÑ̵Ļ·¾³µÄ×ÛºÏ×÷ÓÃËùÖ¡£±¾Ñо¿Ö¼ÔÚµ÷²é ETS¶Ô·Î¹¦ÄܵÄÓ°Ïì¼°ÕÒ³öÆÀ¹À·ÎËðÉ˵Ä×îÃô¸ÐµÄ¹¦ÄÜÐÔÖ¸±ê¡£ Éè¼Æ£ººá¶ÏÃæµ÷²é¡£ ·¶Î§£º¶ÔÖÐѧѧÉúµÄ½¡¿µµ÷²é¡£ ¶ÔÏó£º80ÃûÇàÉÙÄêÄÐÐÔ£¬Æ½¾ùÄêÁä (16¡À1) Ë꣬·ÖΪ3×飺ÎüÑÌ×é21Ãû£¬²»ÎüÑÌ×é30Ãû£¬±»¶¯ÎüÑÌ×é29Ãû¡£ ²â¶¨£ºÓ¦Óñê×¼»¯µÄÎʾíµ÷²éÑо¿¶ÔÏ󼰯䏏ďµÄÎüÑÌϰ¹ß£¬²â¶¨ÄòÖеĿÉÌæÄþˮƽ¡¢¿ÉÌæÄþ /¼¡ËáµÄ±ÈÀý (CCR) ºÍ·Î¹¦ÄÜ [°üÀ¨·ÎÈÝÁ¿¡¢·Î¹¦Äܶ¯Á¦²ÎÊýºÍµ¥´ÎºôÎü·ÎÒ»Ñõ»¯Ì¼ÃÖÉ¢Á¿ (DLCO)]¡£ ½á¹û£º±»¶¯ÎüÑÌÕßµÄ²ÐÆøÁ¿¸ßÓÚ²»ÎüÑÌÕߣ¬¶øÔÚ 25% FVCʱµÄ×î´óºôÆøÁ÷Á¿ (MEF25) ºÍDLCOÔòµÍÓÚ²»ÎüÑÌÕß¡£Ä¸Ç×»³ÔÐÆÚ¼äÎüÑ̵Ķùͯ±»¶¯ÎüÑÌÕß MEF25¡¢DLCO¡¢Ò»Ñõ»¯Ì¼×ªÔËϵÊýºÍ·ÎÅÝ -ëϸѪ¹ÜĤÃÖÉ¢ÄÜÁ¦ (DM)£¬ÏÔÖøµÍÓÚĸÇ×ÔÚ»³ÔÐÆÚ¼ä½äÑ̵ı»¶¯ÎüÑÌÕß¡£È»¶ø£¬Ä¸Ç×ÔÚ»³ÔÐÆÚ¼ä ½äÑ̵ı»¶¯ÎüÑÌÕߣ¬±ÈÄÇЩĸÇ×´Ó²»ÎüÑ̵Ķùͯ±»¶¯ÎüÑÌÕßµÄ MEF25ºÍDMµÄÖµ¶¼µÍ (P < 0.05)£¬Õâ±íÃ÷±»¶¯ÎüÑ̶ԶùͯÔçÆÚ·ÎË𺦵ĸºÃæÓ°Ïì²»ÒÀÀµÓÚĸÇ×ÔÚ»³ÔÐÆÚ¼äµÄÎüÑÌϰ¹ß¡£ÔÚÎüÑÌÕß (r = -0.63, P < 0.01) ºÍ±»¶¯ÎüÑÌÕß (r = -0.91£¬P < 0.001) ÖÐCCRºÍDLCOÖ®¼äµÄ¹ØÏµÎª¸ºÏà¹Ø£¬¶øÔÚ²»ÎüÑÌÕßÖв»´æÔÚÕâÖÖ¹ØÏµ (r = 0.26£¬P > 0.05)£¬ÌáʾÁ½ÕßÖ®¼ä´æÔÚ¼ÁÁ¿Ð§Ó¦¹ØÏµ¡£ ½áÂÛ£º½¡¿µÄÐÐÔÇàÉÙÄ굱ǰETSµÄÇé¿öÓëÆä·Î¹¦ÄÜËðº¦Óйأ¬¶øÓëÆäĸÇ×ÔÚ»³ÔÐÆÚ¼äµÄÎüÑÌÇé¿öÎÞ ¹Ø¡£²â¶¨¾²Ì¬·ÎÈÝÁ¿ºÍDLCO¿ÉÄÜ»áµÃµ½¸ü¶àµÄÐÅÏ¢¡£ ¹Ø¼ü´Ê£ºÏãÑÌ (cigarette); ÃÖÉ¢·ÎÈÝÁ¿ (diffsion lung capacity); ·Î¹¦ÄÜ (lung function); ±»¶¯ÎüÑÌ (passive smoking); ·ÎÁ¿²â¶¨·¨ (spirometry)
£¨»Æ´ºÆ¼ Ò룻ʩ»ÀÖРУ£© ¡¾Ó¢ÎÄÔ¼þÇë²ÎÔÄChest, 2004; 125: 1387-1393¡¿
ÄÒÐÔÏËά»¯»¼Õߵķι¦Äܼ°ÌµÒº²úÉúµÄÑо¿ ¡¡ ¡ª¡ª ¶Ô¸ßƵÕðµ´ßµ»÷¼¼Êõ×°Öü°±ê×¼ÐØÇ»ÀíÁƽøÐбȽϵÄÊÔÑéÐÔÑо¿
John H. Marks, MD, FCCP; Karyl L. Hare, RN, CDE; Robert A. Saunders, RRT; and Douglas N. Homnick, MD, MPH, FCCP From the Pediatric Pulmonary Division, Department of Pediatrics, Michigan State University, Kalamazoo Center for Medical Studies (Drs. Marks and Homnick, and Ms. Hare), and Pulmonary Function Laboratory, Bronson Methodist Hospital (Mr.Saunders), Kalamazoo, MI. Correspondence to: John H. Marks, MD, FCCP, Department of Pediatrics, Michigan State University, Kalamazoo Center for Medical Studies, 1000 Oakland Dr, Kalamazoo, MI 49008; e-mail: marks@kcms. msu. edu
Ä¿µÄ£º·ÖÎöÄÒÐÔÏËά»¯ (CF) »¼Õ߷ι¦Äܵļ±ÐԸı䡢̵ҺµÄ²úÉú¼°Âö³åѪÑõ¶¨Á¿²â¶¨£¬¶Ô¸ßƵÕð µ´ßµ»÷ (PTHF) ×°Öà (Vortran Medical Technology 1; Sacramento, CA) ºÍ±ê×¼ÊÖ¶¯ÐØÇ»ÎïÀíÖÎÁÆ (CPT) ½øÐбȽϡ£ Éè¼Æ£ºËæ»ú½»²æÑо¿¡£ µØµã£º´óѧ¸½Êô¡¢»ùÓÚÉçÇøµÄCFÖÐÐÄ¡£ ¶ÔÏó£º10ÃûCFÁÙ´²Îȶ¨ÆÚ»¼Õß (ÄêÁä10 ~ 21Ë꣬ƽ¾ùÄêÁä15.3Ëê)£¬ÆäShwachmanÆÀ·ÖΪ55 ~ 95·Ö (ƽ¾ù75·Ö)¡£ ·½·¨£ºÊ¹ÓÃÁ½ÖÖÖÎÁÆ·½°¸£º(1) ¾ÅçÎíÆ÷¸øÓèɳ¶¡°·´¼2.5 mg£¬È»ºóÓñê×¼CPT£»(2) ¾PTHF×°ÖøøÓèɳ¶¡°·´¼2.5 mg£¬²»ÓÃCPT¡£ ½á¹û£ºÑо¿½á¹ûÆÀ¼Û°üÀ¨ÖÎÁƺó4 hÐзι¦Äܲⶨ (PFT) ¼°ÖÎÁƺó4 hÄÚ̵Һ¶¨Á¿£¬ÔÚÖÎÁƹý³ÌÖÐÐÐÂö³åѪÑõ¶¨Á¿²â¶¨£¬Ñо¿½áÊøÊ±¶Ô»¼Õß½øÐÐÂúÒâ¶ÈÎʾíµ÷²é¡£ËäÈ»¾Á½ÖÖ·½·¨ÖÎÁƺó»¼ÕßµÄ²ÐÆø ÈÝ»ý¶¼ÓÐϽµÇ÷ÊÆ£¬µ«4 hµÄPFT²ÎÊý²¢Ã»ÓÐÏÔÖø¸Ä±ä¡£PTHF×éÅÅ̵Á¿ÉÔ¶àÓÚCPT×飬µ«¸Ã½á¹û ²¢ÎÞͳ¼ÆÑ§ÒâÒå¡£Á½×éÖÎÁƹý³ÌÖм°ÖÎÁƺó¾ùδ·¢ÉúѪºìµ°°× -ÑõÈ¥±¥ºÍÏÖÏó¡£ÓÐÒ»Ãû»¼Õß¾CPTÖÎÁƺóÇá΢¿©Ñª¡£PTHFÖÎÁƺóδ·¢ÏÖÓв»Á¼·´Ó¦·¢Éú¡£Îʾíµ÷²é½á¹ûÖУ¬ 8Ãû»¼ÕßÈÏΪPTHF×°ÖñãÓÚʹÓã¬6Ãû»¼Õ߸üÔ¸ÒâÑ¡ÔñʹÓÃPTHF ×°Öᣠ½áÂÛ£º±¾Ð¡¹æÄ£ÊÔÑéÐÔÑо¿Ìáʾ£¬PTHF×°ÖÃΪһ°²È«¡¢ÓÐЧµÄ CF»¼Õ߯øµÀÇå³ý·½·¨¡£ ¹Ø¼ü´Ê£ºÐØÇ»ÎïÀíÖÎÁÆ (chest physiotherapy); ÄÒÐÔÏËά»¯ (cystic fibrosis ); ·ÎÄÚßµ»÷ (intrapulmonary percussion); ð¤ÒºÇå³ý (mucus clearance); ·Î¹¦ÄÜ (pulmonary function)
£¨ÁõÓ± Ò룻ÁõÖ¾ У£© ¡¾Ó¢ÎÄÔ¼þÇë²ÎÔÄChest, 2004; 125: 1507-1511¡¿
ÎüÑ̶ԴóÊóÈéÏÙ°©×ªÒÆÄ£ÐÍ·Î×ªÒÆµÄ×÷ÓÃ
Susan Murin, MD, MSc, FCCP; Kent E. Pinkerton, PhD; Neil E. Hubbard, PhD; and Kent Erickson, PhD From the Division of Pulmonary and Critical Care Medicine (Dr. Murin), Department of Internal Medicine, Department of Cell Biology and Human Anatomy (Drs. Hubbard and Erickson), University of California Davis School of Medicine, Davis, CA; and Center for Health and the Environment (Dr. Pinkerton), University of California, Davis, CA. Correspondence to: Susan Murin, MD, MSc, FCCP, 4150 V St,Suite 3400, Sacramento, CA 95817; e-mail: sxmurin@ucdavis. edu
±³¾°£ºÎüÑ̸¾Å®ÈéÏÙ°©ËÀÍöÂʸßÓÚ²»ÎüÑ̸¾Å®¡£ÒÑÓÐÁ÷Ðв¡Ñ§Ñо¿ÌáʾÎüÑÌÓëÈéÏÙ°©·Î×ªÒÆÓйØÁª¡£ Ä¿µÄ£ºÑо¿ÎüÑÌÓë´óÊóÈéÏÙ°©×ªÒÆÄ£ÐÍ·Î×ªÒÆÖ®¼äµÄ¹ØÏµ¡£ Éè¼Æ£ºÇ°Õ°ÐÔ¡¢Ëæ»úÑо¿¡£ µØµã£º¶¯ÎïÑо¿ÊµÑéÊÒ¡£ ¶ÔÏ󣺴ÆÐÔ³ÉÊìBAlB/cAnN´óÊó¡£ ·½·¨£º´óÊó±»Ëæ»ú·ÖΪʵÑé×éºÍ¶ÔÕÕ×飬ʵÑé×é´óÊóÖÃÓÚÌØÊâµÄÏäÄÚ£¬±©Â¶ÓÚÏãÑÌÑÌÎíÖУ¬ÏãÑÌ ÑÌÎíµÄŨ¶È½üËÆÓÚÕý³£ÎüÑÌÁ¿£»¶ÔÕÕ×鱩¶ÓÚ¾¹ýÂËµÄ¿ÕÆøÖС£±©Â¶1 wkºó£¬´óÊó¾Î²¾²Âö·Ö±ð×¢Éä3ÖÖŨ¶È (50 000¡¢100 000¡¢150 000¸öϸ°û/100 mL) µÄÊóÈéÏÙÖ×Áöϸ°û (Ö×Áöϸ°ûϵ4526)£¬3 wkºóɱËÀ´óÊ󣬲ⶨÊÇ·ñÓзÎ×ªÒÆ²¢¼ÆÊý·Î×ªÒÆÁ¿¡£ ½á¹û£ºÃ¿Ò»ÖÖ×¢ÉäµÄÖ×Áöϸ°ûŨ¶ÈµÄʵÑé×鶯Îï·Îƽ¾ù×ªÒÆ¸ººÉ¾ù´óÓÚ¶ÔÕÕ×飺 50 000¸öϸ°û/100 mLΪ9.8¶Ô4.8 mm3, P < 0.01; 100 000¸öϸ°û/100 mLΪ34.5¶Ô17.4 mm3, P < 0.10£»150 000¸öϸ°û/100 mLΪ54.0¶Ô31.5 mm3£¬P < 0.05¡£±¾Ñо¿½á¹û¸ü´ó³Ì¶ÈÉÏÒÀ¾ÝµÄÊÇÿ¸ö¶¯Îï·Î×ªÒÆ½á½ÚµÄÊýÄ¿£¬ ¶ø²»Êǽá½Ú´óС £º50 000¸öϸ°û/100 mLΪ8.7¶Ô4.8£¬P < 0.001; 100 000¸öϸ°û/100 mLΪ24.3 ¶Ô 14.0£¬P > 0.10£»150 000¸öϸ°û/100 mLΪ42.0¶Ô20.1£¬P < 0.02¡£ ½áÂÛ£º±©Â¶ÓÚÏãÑÌÑÌÎíÓë´óÊóÈéÏÙ°©×ªÒÆÄ£ÐÍ·Î×ªÒÆ×ܸººÉÁ¿µÄÔö¼ÓÏà¹ØÁª¡£ÕâÏîÑо¿ÎªÎüÑÌÔÚ°© Ö¢×ªÒÆ¹ý³Ì²úÉúÓк¦×÷ÓÃÌṩÁËʵÑéÒÀ¾Ý£¬²¢Ìá³öÁËÎüÑÌÕßÈéÏÙ°©ËÀÍöÂÊÔö¼ÓµÄ¿ÉÄÜ»úÖÆ¡£ ¹Ø¼ü´Ê£ºÈéÏÙ°© (breast cancer); ×ªÒÆ (metastasis); ÎüÑÌ (smoking)
£¨ÁõÓ± Ò룻ÁõÖ¾ У£© ¡¾Ó¢ÎÄÔ¼þÇë²ÎÔÄChest, 2004; 125: 1467-1471¡¿
Î£ÖØÖ¢»¼ÕßÑÖ¤ÓªÑøÖ§³ÖÖÎÁƲݰ¸ÊµÊ©Ç°ºóµÄ½á¹ûÑо¿
Juliana Barr, MD; Marketa Hecht, MD; Kara E. Flavin, BA; Amparo Khorana, MSRD, CNSD; and Michael K. Gould, MD, MS, FCCP From the Department of Veterans Affairs Palo Alto Health Care System (Drs. Barr and Gould, and Ms. Khorana), Palo Alto, CA; and the Department of Anesthesia (Drs. Barr and Hecht) School of Medicine, and the Division of Pulmonary and Critical Care Medicine (Dr. Gould and Ms. Flavin), Stanford University, Stanford, CA. Correspondence to: Juliana Barr, MD, Associate Professor of Anesthesia, Stanford University School of Medicine, Anesthesiology Service (112A), VA Palo Alto Health Care System, 3801 Miranda Ave, Palo Alto, CA 94304; e-mail: barrj@stanford. edu
Ä¿µÄ£ºÈ·¶¨ÔÚICUÖÐÊµÊ©ÓªÑøÖ§³ÖÖÎÁÆÊÇ·ñ¿ÉÒÔÔö¼Ó»¼Õß³¦ÄÚÓªÑøÊ¹ÓÃÂÊ£¬Ê¹»¼Õß¾¡Ôç½øÊ³¼°¸ÄÉÆ Ô¤ºó¡£ Éè¼Æ£º¶ÔICUÄÚÎ£ÖØÖ¢²¡ÈËÔÚÒýÈëÑ֤ҽѧָµ¼Ç°ºóËù½øÐеÄÓªÑøÖ§³ÖÖÎÁƵÄǰհÐÔÆÀ¹À¡£ µØµã£ºÁ½Ëù½ÌѧҽԺÖеÄÄÚ-Íâ¿ÆICU¡£ ¶ÔÏó£ºÑ¡È¡200ÃûÔÚICUÖÎÁƳ¬¹ý48 hµÄÎ£ÖØ³ÉÄ겡ÈË¡£ÆäÖÐ100ÈËÈëÑ¡¡°ÊµÊ©Ç°×顱£¬ÁíÒ»×éΪ¡°ÊµÊ©ºó×顱¡£ ·½·¨£ºÊµÊ©ÑÖ¤·½°¸µÄICUÓªÑøÖ§³ÖÖÎÁÆ¡£ ²âÁ¿ºÍ½á¹û£º²â¶¨ÓªÑø½á¹ûµÄÖ¸±ê°üÀ¨½ÓÊܳ¦ÄÚÓªÑøµÄ²¡ÈËÊýÁ¿¡¢¿ªÊ¼ÓªÑøÖÎÁƵÄʱ¼ä¼°¸øÓèÓªÑø Ö§³ÖµÚ4ÌìʱµÄÄ¿±êÈÈÁ¿ÉãÈë¡£ÁÙ´²½á¹ûµÄÆÀ¼ÛÖ¸±ê°üÀ¨»úÐµÍ¨ÆøµÄ³ÖÐøÊ±¼ä¡¢ÔÚICU¼°Ò½ÔºµÄס Ժʱ¼ä (LOS) ÒÔ¼°ÔºÄÚËÀÍöÂÊ¡£¡°ÊµÊ©ºó×顱µÄ²¡È˽ϡ°ÊµÊ©Ç°×顱µÄ²¡ÈËͨ¹ý³¦µÀιʳµÄ´ÎÊý ¸ü¶à (78%¶Ô68%£»P=0.08)¡£¾¶Ô¼²²¡ÑÏÖØ³Ì¶È¡¢»ùÏßÓªÑø×´¿ö¼°ÆäËûÒòËØ½øÐÐУÕýºó£¬¸Ã½á¹û ¾ßÓÐÏÔÖøµÄͳ¼ÆÑ§ÒâÒå (±ÈÖµ±ÈΪ2.4£¬95%CIΪ1.2 ~ 5.0£¬P=0.009)¡£Á½×éÓªÑøÖ§³ÖµÚ4ÌìµÄιʳµÄʱ¼ä¼°ÈÈÁ¿ÉãÈëֵûÓвî±ð¡£¡°ÊµÊ©ºó×顱µÄƽ¾ù»úÐµÍ¨Æø³ÖÐøÊ±¼ä½Ï¶Ì [(17.9¡À31.3) ¶Ô (11.2¡À19.5) d£¬P=0.11]£¬¾¶ÔÄêÁä¡¢ÐԱ𡢼²²¡ÑÏÖØ³Ì¶È¡¢¸øÒ©Í¾¾¶¡¢»ùÏßÓªÑø×´¿ö¡¢ÓªÑøÖ§³Ö ÀàÐ͵ȽøÐÐУÕýºó£¬¸Ã²îÒì¾ßÓÐÏÔÖøµÄͳ¼ÆÑ§ÒâÒå (P=0.03)¡£Á½×é¼ä ICU»òסԺLOSûÓвî±ð¡£½ÓÊܳ¦ÄÚÓªÑø»¼ÕßµÄËÀÍöΣÏնȽµµÍÁË56% (·çÏÕ±ÈΪ0.44£¬95%CIΪ0.24 ~ 0.80£¬P=0.007)¡£ ½áÂÛ£º°´ÕÕÑÖ¤·½°¸½øÐеÄÓªÑøÖ§³ÖÖÎÁÆÔö¼ÓÁËICU»¼Õß½ÓÊܳ¦ÄÚÓªÑøµÄ¿ÉÄÜÐÔ£¬Ëõ¶ÌÁË»úÐµÍ¨Æø ʱ¼ä¡£³¦ÄÚÓªÑøÓë¸ÃÑо¿Öл¼ÕßËÀÍöΣÏÕÐԵĽµµÍ¾ßÓÐÏà¹ØÐÔ¡£ ¹Ø¼ü´Ê£ºÎ£Ö¢»¤Àí (critical care); ³¦ÄÚÓªÑø (enteral nutrition); ÖØÖ¢¼à»¤ (intensive care); ÓªÑø·½°¸ (nutritional protocols); ÓªÑøÖ§³ÖÖÎÁÆ (nutritional management); ½á¹ûÑо¿ (outcomes research); ³¦ÍâÓªÑø (parenteral nutrition)
£¨ÁõÓ± Ò룻ÁõÖ¾ У£© ¡¾Ó¢ÎÄÔ¼þÇë²ÎÔÄChest, 2004; 125: 1446-1457¡¿
ÓÃ30 d½á¹ûÔ¤²âËÀÍöΣÏÕ¶È ¡¡¡¡¡¡ ¡ª¡ª ÖØÖ¢¼à»¤Ò½ÁÆÖÊÁ¿ÆÀ¼ÛµÄʵÓÃÐÔ·½·¨
Petra L. Graham, MS; and David A. Cook, MBBS From Statistics (Ms. Graham), School of Mathematical and Physical Sciences, University of Newcastle, Callaghan; and Intensive Care Unit (Dr. Cook), Princess Alexandra Hospital,Woolloongabba, Australia. Correspondence to: Petra L. Graham, MS, Statistics, School of Mathematical and Physical Sciences, Building “V”, University of Newcastle, Callaghan, NSW 2308, Australia, e-mail: pgraham@maths. newcastle. edu. au
Ä¿µÄ£ºÓÃ30 dËÀÍöÂÊÆÀ¼ÛδУÕýµÄ¼±ÐÔÉúÀíºÍÂýÐÔ½¡¿µÆÀ¹ÀÖ¸±ê (APACHE) ¢ó¼°ÓëÆäÀàËÆµÄסԺËÀÍöÂÊÆÀ¹ÀÄ£ÐÍ£¬²¢Éè¼ÆÒ»¸ö¼òÒ×·½·¨¹æ·¶µ±µØ×¡ÔºÎ£ÖسÉÄ겡È˵Ä30 dסԺËÀÍöÂÊ£¬ÓÃÓÚÖÊÁ¿¹ÜÀí¼°·çÏÕ¼à²â¡£ Éè¼Æ£ºÎÞ¸ÉÔ¤µÄ¹Û²ìÐÔÑо¿¡£ ¶ÔÏó£º×Ô1995Äê1ÔÂ1ÈÕÖÁ1999Äê12ÔÂ31ÈÕ¼äÁ¬ÐøµÄ5 278ÃûסԺ»¼Õß¡£ ×ÊÁÏ£ºÇ°Õ°ÐÔÊÕ¼¯ÈË¿Úͳ¼ÆÑ§Êý¾Ý¡¢Õï¶Ï½á¹û¡¢ÉúÀíÖ¸±ê¡¢ÊµÑéÊÒ¼ìÑé½á¹û¼°³öÈëÔºÇé¿ö¡£ ½á¹û£ºAPACHE ¢óËÀÍöÂÊÔ¤²âÖµ [½ÓÊÕÕß¹¤×÷ÌØÕ÷ (ROC) ÇúÏßÃæ»ý] Äܼ«ºÃµØÏÔʾ30 d½á¹û (ROCÃæ»ýΪ0.89) ¼°×¡Ôº½á¹û (ROCÃæ»ýΪ0.89) ¼äµÄÇø±ð¡£´ÓУ׼ÇúÏß¼°Hosmer-Lemeshowͳ¼Æ±íµÃµ½ËùÓйØÓÚ30 d½á¹ûÄ£Ð͵ÄУÕý½á¹û£¬³ýÁËδУÕýµÄAPACHE ¢óÄ£ÐÍ¡£ÐµļòÒ×·çÏÕµ÷ÕûÄ£ÐÍÄܶÔÊý¾ÝµÄÕ¹¿ªºÍ¼ìÑé½øÐнϺõؼø±ðºÍУÕý£¬ÆäROCÃæ»ýΪ0.88 (Õ¹¿ªÊý¾Ý) ºÍ0.87 (¼ìÑéÊý¾Ý)¡£¸ÃÐÂÄ£Ð͵ÄУÕýÖµÓëAPACHE ¢óÄ£ÐÍÏ൱¡£ ½áÂÛ£º¶ÔÖÊÁ¿ÆÀ¼Û¶øÑÔ£¬30 dסԺËÀÍöÂÊ¿É×÷Ϊȷ¶¨³öÔº»¼Õß´æ»îµÄÒ»ÏîÔ¤ºóÖ¸±ê¡£ÐµÄlogistic »Ø¹éÄ£ÐÍ֤ʵ£¬Í¨¹ýÈô¸É½âÊÍÐԵıäÁ¿¿ÉÒÔ½¨Á¢Æð¾ßÓкܺÃУÕý¼°¼ø±ðÄÜÁ¦µÄµ±µØÄ£ÐÍ¡£ ¹Ø¼ü´Ê£ºlogistic»Ø¹é (logistic regression); ÖÊÁ¿¼à²â (quality monitoring); ·çÏÕµ÷Õû (risk adjustment); ·çÏÕÆÀ¹À (risk assessment); ¹£ËÀ (infarction); ÔÙ¹à×¢ (reperfusion)
£¨ÁõÓ± Ò룻ÁõÖ¾ У£© ¡¾Ó¢ÎÄÔ¼þÇë²ÎÔÄChest, 2004; 125: 1458-1466¡¿
Ä«Î÷¸çÏø´µÄÇ÷ÊÆ ¡ª¡ª Ò»¼ÒÈ«¹úÐÔÒ½ÁÆ»ú¹¹11Äê×ÊÁÏ·ÖÎö
Mario H. Vargas, MD, MS, FCCP; Guillermo S. Diaz-Mejia, MD, FCCP; Maria E. Y. Furuya, MD, PhD; Jorge Salas, MD; and Alejandro Lugo From the Unidad de Investigacion Medica en Epidemiologia Clinica (Dr. Vargas) and Division de Especialidades Medicas (Dr. Furuya), Hospital de Pediatria, Centro Medico Nacional Siglo XXI; and Programa Nacional de Asma (Dr. Diaz-Mejia and Mr. Lugo), Instituto Mexicano del Seguro Social; and Instituto Nacional de Enfermedades Respiratorias (Dr. Salas), Mexico DF, Mexico. Correspondence to: Mario H. Vargas, MD, MS, FCCP, Unidad de Investigacion Medica en Epidemiologia Clinica, Hospital de Pediatria, Centro Midico Nacional Siglo XXI, IMSS, Av. Cuauhtemoc 330, CP 06720, Mexico DF, Mexico; e-mail: mhvargasb@yahoo. com. mx
Ä¿µÄ£ºÔÚÐí¶à¹ú¼ÒÏø´µÄÁ÷ÐÐÈÔ³ÊÔö¼ÓÇ÷ÊÆ¡£È»¶ø×î½üһЩÎÄÏ×Ö¸³ö£¬ÕâÖÖÇ÷ÊÆÕýÔÚÖÕÖ¹¡£ÎÒÃÇ µÄÑо¿Ö¼ÔÚµ÷²éÄ«Î÷¸çÏø´µÄÁ÷ÐÐÇ÷ÊÆ¡£ Éè¼Æ£º¶Ô1991ÖÁ2001ÄêÌṩ¸øÏø´»¼ÕߵĽ¡¿µ·þÎñ×ÊÁϽøÐлعËÐÔ·ÖÎö¡£ µØµã£ºInstituto Mexicano del Seguro Social£¬Ä«Î÷¸ç×î´óµÄÈ«¹úÐÔÒ½ÁÆ»ú¹¹ (ÓµÓÐÔ¼24 000 000 ~ 32 000 000±£ÏÕÈËȺ)¡£ ¶ÔÏ󣺸÷¸öÄêÁä×éµÄ»¼Õß¡£ ¸ÉÔ¤ÒòËØ£ºÎÞ¡£ ·½·¨ºÍ½á¹û£ºÖÁ1997ÄêΪֹ£¬ÔÚ¼Òͥҽʦ´¦¾ÍÕï (FPOVs£¬½öÖ¸ÐÂÕï¶ÏµÄ²¡Àý)¡¢¼±Õï¾ÍÒ½ (ERVs) ºÍ³öÔº (HDs) ¼Ç¼ÖУ¬ÓëÏø´Ïà¹ØµÄ½¡¿µ·þÎñ£¬ÎÞÂÛÊÇÒÔ¾ø¶ÔÊýÁ¿±íʾ»¹Êǰ´Õ¼±£ÏÕÈËÊýµÄ±ÈÀýÀ´ ±íʾ£¬¶¼ÔÚ½øÐÐÐÔÔö¼Ó¡£1997ÄêÒÔºó£¬Ïø´Ïà¹ØµÄ½¡¿µ·þÎñµÄÊýÁ¿ºÍ±ÈÀýÒѾϽµ£¬ÕâÖÖÇ÷ÊÆÔÚ 0 ~ 4¡¢5 ~ 14¡¢15 ~ 44¡¢45 ~ 64ËêµÄÄêÁä×é¾ù¿É¿´µ½¡£ÔÚÿÄêËùÓеÄFPOVs²¡ÀýÖУ¬Ïø´Ô¼Õ¼ 0.4%£¬1997ÄêºóÕâ¸ö°Ù·Ö±È¿ªÊ¼Ï½µ¡£Í¬ÑùµØ1997ÄêÇ°Ïø´ÔÚ ERVsºÍHDs²¡ÀýÖеİٷֱȲ»¶ÏÔö¼Ó£¬´ËºóѸËÙϽµ¡£ ½áÂÛ£ºÔÚËùÓÐÒ½ÁÆ»ú¹¹£¬½üÄêÀ´Ïø´Ïà¹ØµÄ½¡¿µ·þÎñµÄ¾ø¶ÔÊýºÍÏà¶ÔÊý¶¼ÔÚϽµ¡£ÕâÌáʾз¢Ïø´ ²¡ÀýµÄÁ÷ÐÐÕýÔÚÖÕÖ¹ºÍ (»ò) Ïø´ÒѾµÃµ½Á¼ºÃµØ¿ØÖÆ¡£ ¹Ø¼ü´Ê£ºÏø´Á÷ÐÐ (asthma epidemic); Ïø´Á÷Ðв¡Ñ§ (asthma epidemiology); ½¡¿µ·þÎñ (health services); ʱ¼äÇ÷ÊÆ (time trend)
£¨Ðì·å Ò룻Éò»ªºÆ У£© ¡¾Ó¢ÎÄÔ¼þÇë²ÎÔÄChest, 2004; 125: 1993-1997¡¿
COPD»¼Õߵļ±ÐÔºôÎüµÀ¸ÐȾÒÔ¼°Á÷¸ÐÒßÃç½ÓÖÖµÄÔ¤·ÀЧ¹û ¡ª¡ª Ò»ÏîËæ»ú¶ÔÕÕÑо¿
Phunsup Wongsurakiat, MD, FCCP; Khun Nanta Maranetra, MD; Chantapong Wasi, MD; Uraiwan Kositanont, MD; Wanchai Dejsomritrutai, MD, MSc; and Suchai Charoenratanakul, MD, FCCP From the Division of Respiratory Disease and Tuberculosis, Department of Medicine (Drs. Wongsurakiat, Maranetra, Dejsomritrutai, and Charoenratanakul), and Department of Microbiology (Drs. Wasi and Kositanont), Siriraj Hospital, Mahidol University, Bangkok, Thailand. Correspondence to: Phunsup Wongsurakiat, MD, Division of Respiratory Disease and Tuberculosis, Department of Medicine, Siriraj Hospital, Mahidol University, Bangkok 10700, Thailand; e-mail: sipwo@mahidol. ac. th
Ä¿µÄ£ºÑо¿Á÷¸ÐÒßÃç½ÓÖÖ¶ÔCOPD»¼ÕßµÄÁ÷¸ÐÏà¹Ø¼±ÐÔºôÎüµÀ¸ÐȾ (ARI) ºÍËùÓÐARIµÄÔ¤·ÀЧ¹û£¬²¢Ñо¿ËüÓëÆøÁ÷×èÈû³Ì¶ÈµÄ¹ØÏµ¡£ Éè¼Æ£º·Ö²ã¡¢Ëæ»ú¡¢Ë«Ã¤ºÍ°²Î¿¼Á¶ÔÕÕÊÔÑé¡£ µØµã£º´Ó1997Äê6ÔÂÖÁ1998Äê11ÔÂÔÚÒ»Ëù´óѧҽԺ½øÐС£ ¶ÔÏóÓë·½·¨£º125ÀýCOPD»¼Õ߸ù¾ÝFEV1 ·Ö³ÉÇá¡¢ÖС¢ÖضȲ»Í¬²ã´Î¡£ÔÚÿ¸ö²ã´ÎÖÐÔÙËæ»ú·ÖΪÒßÃç½ÓÖÖ×é (¹²62Àý»¼Õߣ¬½ÓÖÖ´¿»¯µÄÈý½éÌåÁѽⲡ¶¾ÒßÃç) ºÍ°²Î¿¼Á×é (¹²63Àý»¼Õß)¡£ ¼ì²â£º¼Ç¼ËùÓÐARIµÄ·¢×÷´ÎÊýºÍÑÏÖØ³Ì¶È¡£ÑÏÖØ³Ì¶È·ÖΪÃÅÕïÖÎÁÆ¡¢×¡ÔºÖÎÁƺÍÐèÒª»úÐµÍ¨Æø ÖÎÁÆ¡£Í¬Ê±¼Ç¼Á÷¸ÐÏà¹ØARIµÄ·¢×÷´ÎÊýºÍÑÏÖØ³Ì¶È¡£ ½á¹û£ºÁ÷¸ÐÏà¹ØARIµÄ·¢ÉúÂÊÔÚ°²Î¿¼Á×éºÍÒßÃç½ÓÖÖ×é·Ö±ðΪ28.1/100ºÍ6.8/100ÈËÄê (Ïà¶ÔΣÏÕ¶ÈRRΪ0.24, P = 0.005£»ÒßÃçÓÐЧÐÔΪ76%)¡£ÔÚ°²Î¿¼Á×éÖУ¬Çá¡¢ÖС¢ÖضÈCOPD»¼ÕßÁ÷¸ÐÏà¹Ø ARIµÄ·¢ÉúÂÊ·Ö±ðΪ28.2¡¢23.8ºÍ31.2/100ÈËÄꣻ¶øÔÚÒßÃç½ÓÖÖ×éÖУ¬Çá¡¢ÖС¢ÖضÈCOPD»¼Õß Á÷¸ÐÏà¹ØARIµÄ·¢ÉúÂÊ·Ö±ðΪ4.5¡¢13.2ºÍ4.6/100ÈËÄê¡£ÔÚÒßÃç½ÓÖÖ×éÖУ¬Çá¡¢ÖС¢ÖضÈCOPD »¼ÕßµÄRR·Ö±ðΪ0.16 (P = 0.06)¡¢0.55 (P = 0.5) ºÍ0.15 (P = 0.04); ÒßÃç½ÓÖÖµÄÓÐЧÐÔ·Ö±ðΪ84%¡¢45%ºÍ 85%¡£Ë«±äÁ¿·ÖÎöÏÔʾ£¬Á÷¸ÐÒßÃç½ÓÖÖµÄÓÐЧÐÔ²»ÒòCODPÑÏÖØ³Ì¶È¡¢ºÏ²¢¼²²¡¡¢ÄêÁä¡¢ ÐÔ±ðºÍĿǰÎüÑÌ×´¿öµÄ²»Í¬¶ø·¢Éú±ä»¯¡£ËùÓÐARIµÄ·¢ÉúÂʺÍÑÏÖØ³Ì¶ÈÔÚ°²Î¿¼Á×éºÍÒßÃç½ÓÖÖ×éÖ®¼ä ÎÞ²îÒì¡£ ½áÂÛ£º²»ÂÛCOPDµÄÑÏÖØ³Ì¶ÈÈçºÎ£¬Á÷¸ÐÒßÃç½ÓÖÖÄܸßЧԤ·ÀÁ÷¸ÐÏà¹ØARIµÄ·¢Éú¡£Á÷¸ÐÒßÃç½Ó ÖÖ¶ÔÓÚÆäËûÔÒòÒýÆðµÄARIûÓÐÔ¤·À×÷Óá£Á÷¸ÐÒßÃç½ÓÖÖÔ¤·ÀËùÓÐARI·¢ÉúµÄÓÐЧÐÔÈ¡¾öÓÚÁ÷¸ÐÏà ¹ØARIÔÚËùÓÐARIÖÐËùÕ¼µÄ±ÈÀý¡£¶ÔËùÓÐCOPD»¼Õß¶¼Ó¦¸ÃÍÆ¼ö½ÓÊÜÁ÷¸ÐÒßÃç½ÓÖÖ¡£ ¹Ø¼ü´Ê£º¼±ÐÔ¼ÓÖØ (acute excerbation); ÆÕͨ¸Ðð (common cold); סԺ (hospitalization); »úÐµÍ¨Æø (mechanical ventilation); ²¡¶¾¸ÐȾ (viral infection)
£¨Ð»¿¡¸Õ Ò룻ÐìÓÀ½¡ У£© ¡¾Ó¢ÎÄÔ¼þÇë²ÎÔÄChest, 2004; 125: 2011-2020¡¿
ÄÒÐÔÏËά»¯ºÍÏø´¶ùͯºô³öÆøÀäÄýÎïpH ¡ª¡ª Ò»¸öеÄÎÞ´´ÐÔÆøµÀÑ×Ö¢Ö¸±ê£¿
Giovanna E. Carpagnano, MD; Peter J. Barnes, MD, DM, Dsc; Jackie Francis; Nicola Wilson, MD; Andrew Bush, MD; and Sergei A. Kharitonov, MD, PhD From the Department of Thoracic Medicine, National Heart & Lung Institute, Imperial College, London, UK. Correspondence to: Sergei A. Kharitonov, MD, PhD, Department of Thoracic Medicine, National Heart & Lung Institute, Imperial College, Dovehouse St, London SW3 6LY, UK; email: s. kharitonov@imperial. ac. uk
±³¾°£ºÔÚºôÎüϵͳ¼²²¡ÖУ¬ÎÞ´´ÐÔÆøµÀÑ×Ö¢µÄÆÀ¹ÀºÍ¼à²âÊǺÜÖØÒªµÄ¡£ºô³öÆøÀäÄýÎï (EBC) pHÊÇÒ»¸öºÜÓÐÏ£ÍûµÄÖ¸±ê¡£¾¡¹Ü EBC µÄpHÒÑÔÚ³ÉÄêÆøµÀÑ×Ö¢ÐÔ¼²²¡»¼ÕßÖвⶨ£¬µ«ÉÐδÔÚ¶ùͯ»¼ÕßÖÐ Ñо¿¡£ Ä¿µÄ£º±¾Ñо¿Ö¼ÔÚÆÀ¹ÀÄÒÐÔÏËά»¯ (CF) ºÍÏø´¶ùͯEBCµÄpHÊÇ·ñ´æÔÚÒì³££¬²¢Ã÷È·EBC pHÄÜ·ñ×÷ÎªÆøµÀÑ×Ö¢µÄÒ»¸öÖ¸±ê¡£ÔÚ´Ë»ù´¡ÉϽøÒ»²½Ñо¿EBC pH¡¢¼²²¡ÑÏÖØ³Ì¶È¡¢Ñõ»¯Ó¦¼¤Ö®¼äµÄ¹ØÏµ¡£ ¶ÔÏóºÍ·½·¨£ºÎÒÃÇÑо¿ÁË20ÀýCF¶ùͯ [ƽ¾ùÄêÁäΪ (¾ùÊý ± ¾ùÊý±ê×¼Îó) (7+3) Ëê]£¬20ÀýÏø´¶ùͯ [ƽ¾ùÄêÁäΪ (7+2) Ëê] ºÍ15ÀýÄêÁäÅä¶ÔµÄ½¡¿µ¶ùͯ [ƽ¾ùÄêÁäΪ (7+2) Ëê]¡£ÓÃpHÒDzⶨEBC pH¡£ ²âÁ¿ºÍ½á¹û£ºCFºÍÏø´¶ùͯEBC pH½Ï¶ÔÕÕ×é½µµÍ (ƽ¾ùpH·Ö±ðΪ7.23+0.03ºÍ7.42+0.01 ¶Ô 7.85+0.02)¡£EBC pH¡¢Ïø´ÑÏÖØ¶È¡¢CF¸ÐȾ¶ñ»¯Ö®¼ä´æÔÚÏà¹ØÐÔ¡£ºô³öÆøpHºÍºô³öÆø°×ÈýÏ© B4Ũ¶ÈÖ®¼ä³Ê¸ºÏà¹Ø (r=-0.5£»P<0.005)¡£ ½áÂÛ£ºEBC pH²â¶¨ÔÚÆÀ¹ÀÏø´ºÍCF¶ùͯ»¼ÕߵįøµÀÑ×Ö¢ÖпÉÄÜÊÇÓÐÓõÄÖ¸±ê¡£ ¹Ø¼ü´Ê£ºÆøµÀÑ×Ö¢ (airway inflammation); Ïø´ (asthma); ÄÒÐÔÏËά»¯ (cystic fibrosis); ºô³öÆøÀäÄýÎï (exhaled breath condensate); °×ÈýÏ©B4 (leukotriene B4); Ëá¼î¶È (pH )
£¨Ðì·å Ò룻Éò»ªºÆ У£© ¡¾Ó¢ÎÄÔ¼þÇë²ÎÔÄChest, 2004; 125: 2005-2010¡¿
Õý³£ÌåÖØCOPD»¼ÕßÈ«ÉíÔ˶¯ÑµÁ·¶ÔÉíÌå½á¹¹ºÍ¹¦ÄܵÄÓ°Ïì
Frits M. E. Franssen, MD; Roelinka Broekhuizen, MSc; Paul P. Janssen; Emiel F. M. Wouters, PhD, FCCP; and Annemie M. W. J. Schols, PhD From the Department of Respiratory Medicine (Drs. Franssen, Wouters, and Schols, and Ms. Broekhuizen), University Hospital Maastricht, Maastricht; and Asthma Center Hornerheide (Mr. Janssen), Horn, the Netherlands. Correspondence to: Frits M. E. Franssen, MD, Department of Respiratory Medicine, University Hospital Maastricht, PO Box 5800, 6202 AZ, Maastricht, the Netherlands; e-mail: f. franssen@pul. unimaas. nl
±³¾°£º¹Ç÷À¼¡Î®ËõÓ뼡È⹦ÄÜÕϰ¡¢Ô˶¯ÄÍÊÜÐÔ²îºÍCOPD»¼ÕßËÀÍöΣÏÕÐÔµÄÔö¼ÓÓйء£ Ä¿µÄ£º¹Û²ìÕý³£ÌåÖØCOPD»¼ÕßÈ«ÉíÔ˶¯ÑµÁ·¶ÔÉíÌå½á¹¹µÄÓ°Ï죬²¢Ñо¿ÉíÌå½á¹¹±ä»¯Ó빦Äܸıä Ö®¼äµÄ¹ØÏµ¡£ µØµãÓë¶ÔÏó£º50ÀýCOPD»¼Õß [FEV1Ϊ (39 ± 16) %Ô¤¼ÆÖµ] ½øÈëHornerheide·Î¼²²¡¿µ¸´ÖÐÐÄ£¬36ÀýÄêÁ䯥ÅäµÄ½¡¿µ¶ÔÕÕÕßÒ²ÊÕÈë±¾Ñо¿ (×÷Ϊ¶Ô±È»ùÏß)¡£ ·½·¨£º»¼Õ߲μӱê×¼»¯µÄסԺ²¡ÈËÔ˶¯ÑµÁ·¼Æ»®£¬°üÀ¨8 wkʱ¼äÄÚÿÌì´Î¼«Á¿Ì¤³µÔ˶¯¡¢»î¶¯Æ½°å²½ÐС¢¸ºÖØÑµÁ·ºÍÌå²ÙѵÁ·µÈ¡£ ¼ì²â£º²ÉÓÃÉúÎïµç×迹¼¼Êõ²âÁ¿·ÇÖ¬·¾ÖØÁ¿ (FFM)¡£Ã»ÓÐÒ»Àý»¼Õß´ïµ½ÐèÒª¶îÍâ²¹³äÓªÑøµÄ±ê×¼ (ÌåÖØÖ¸Êý ¡Ü 21£¬»òFFMÖ¸ÊýÅ®ÐÔ ¡Ü 15 kg/m2¡¢ÄÐÐÔ ¡Ü 16 kg/m2)¡£²ÉÓÃÖð²½ÔöÁ¿Ì¤³µ²âÊÔ·¨²â¶¨Ô˶¯ÄÜÁ¦¡£²ÉÓÃBiodex²âÁ¦¼Æ (Biodex Medical Corporation; Shirley, NY) ²âÁ¿¹ÉËÄÍ·¼¡µÈ³¤¼¡Á¦¡£ ½á¹û£ºÔÚ»ùÏß״̬ʱ£¬»¼ÕßFFMÏÔÖøµÍÓÚ¶ÔÕÕ×é¡£ÄêÁäºÍFFM¿É¶ÀÁ¢Ô¤²â»¼ÕߵĹÇ÷À¼¡¹¦ÄܺÍÔË ¶¯ÄÜÁ¦¡£¿µ¸´ÑµÁ·ºó£¬ÓÉÓÚFFMÔö¼Ó [´Ó (52.4+7.3) µ½ (53.4+7.7) kg£¬P < 0.05]£¬Ê¹ÌåÖØÃ÷ÏÔÔö¼Ó [´Ó (72.4+9.8) µ½ (73.0+9.4) kg£¬P < 0.05]£¬¶øÖ¬·¾ÖØÁ¿ÓÐϽµÇ÷ÊÆ [´Ó (20.0+6.1) µ½ (19.6 +5.7) kg]¡£×î´ó¹¤×÷ЧÂÊ [´Ó (63+29) µ½ (84+42) W£¬P < 0.001]¡¢×î´óÑõºÄÁ¿ (Vo2max) [´Ó (1 028+307) µ½ (1 229+421) mL/min£¬P < 0.001] ºÍ¹ÉËÄÍ·¼¡µÈ³¤¼¡Á¦ [´Ó (82.5+36.4) µ½ (90.3+34.9) Nm£¬P < 0.05]µÈÖ¸±ê¾ùµÃµ½¸ÄÉÆ¡£°´±ÈÀý¼ÆË㣬FFMµÄ±ä»¯ÂʵÍÓÚ¹¦ÄܵĸÄÉÆ£¬ËüÓëVo 2maxµÄ±ä»¯Ïà¹Ø (r = 0.361, P < 0.05£©£¬µ«ÓëÆäËû¹¦Äܱ仯Î޹ء£ ½áÂÛ£º¶ÔÓÚ°´ÂýÐÔ×èÈûÐԷμ²²¡È«Çò³«Òé·Ö¼¶ÎªIII ~ IV¼¶µÄCOPD»¼Õߣ¬Ç¿»¯Ô˶¯ÑµÁ·±¾Éí¿ÉÒÔÓÕµ¼»úÌåµÄºÏ³É·´Ó¦¡£°´±ÈÀý¼ÆË㣬Ô˶¯ÄÜÁ¦Ìá¸ßºÍ¼¡È⹦ÄܸÄÉÆµÄ³Ì¶È¸ßÓÚFFMµÄÔö¼Ó¡£ ¹Ø¼ü´Ê£ºÀÏÄê (aging); ºÏ³É´úл (anabolic stimulation); ÉíÌå¹¹³É (body composition); ÂýÐÔ×èÈûÐԷμ²²¡ (COPD); Ô˶¯ÄÜÁ¦ (exercise capacity); Ô˶¯ÑµÁ· (exercise training); ·ÇÖ¬·¾ÖØÁ¿ (fat-free mass); ¼¡Á¦ (muscle strength)
£¨Ð»¿¡¸Õ Ò룻ÐìÓÀ½¡ У£© ¡¾Ó¢ÎÄÔ¼þÇë²ÎÔÄChest, 2004; 125: 2021-2028¡¿
Çá¶ÈCOPD»¼Õßȱ·¦ÓÉÉîÎüÆøµ¼ÖÂÖ§Æø¹ÜÊæÕŵÄÄÜÁ¦
Nicola Scichilone, MD; Roberto Marchese, MD; Filippo Catalano, MD; Antonio Maurizio Vignola, MD; Alkis Togias, MD; and Vincenzo Bellia, MD, FCCP From the Istituto di Medicina Generale e Pneumologia, Cattedra di Malattie dell’Apparato Respiratorio, University of Palermo, Palermo, Italy; and the Division of Allergy and Clinical Immunology, and Division of Respiratory and Critical Care Medicine, Department of Medicine, Johns Hopkins University, School of Medicine, Baltimore, MD. Correspondence to: Nicola Scichilone, MD, Istituto di Medicina Generale e Pneumologia, Cattedra di Malattie dell’Apparato Respiratorio, University of Palermo, via Trabucco 180, 90146 Palermo, Italy; e-mail: n. scichilone@libero. it
Ä¿µÄ£ºÌ½ÌÖCOPD»¼ÕßÓÉÉîÎüÆøµ¼ÖÂÖ§Æø¹ÜÊæÕŵÄÄÜÁ¦ÊÇ·ñÊܵ½Ë𺦡£ ·½·¨£º²âÁ¿19ÀýCOPD»¼ÕߺÍ17Àý½¡¿µ¶ÔÕÕÕß [ƽ¾ùÄêÁä·Ö±ðΪ (¾ùÊý+¾ùÊý±ê×¼Îó) (67.8 +7.1) ºÍ (62.5 +9.3) Ëê]ÓÉÉîÎüÆøËùµ¼ÖµÄÖ§Æø¹ÜÊæÕų̶ȡ£Ã¿Î»ÊÜÊÔÕß¾ù¾Ò»ÏµÁе¥¼ÁÁ¿µÄÒÒõ£µ¨¼î¼¤·¢£¬ ʹÉîÎüÆø·Î»îÁ¿ (IVC) ½µµÍ15%ÒÔÉÏ¡£¼¤·¢³É¹¦ºó£¬Ã¿Î»ÊÜÊÔÕßÏÈÁ¬Ðø½øÐÐ4´ÎÉîÎüÆø£¬È»ºóÖØ ¸´²âÁ¿IVC£¬¼ÆËãÓÉÉîÎüÆøËùµ¼ÖµÄÖ§Æø¹ÜÊæÕŰٷÖÂÊ¡£ ½á¹û£ºÉîÎüÆøÇ°£¬IVC´Ó»ùÏßÖµ½µµÍµÄ°Ù·ÖÂÊÔÚÁ½×éÖ®¼äÎÞ²îÒì [COPD×éΪ(20.1 +1.6) %£¬½¡¿µ¶ÔÕÕ×éΪ(22.7 ± 2.4) %£»P = 0.38]; Á½×éËùʹÓõĵ¥¼ÁÁ¿ÒÒõ£µ¨¼îŨ¶ÈµÄÖÐλÊý·Ö±ðΪ20 mg/mL (·¶Î§Îª0.025 ~ 75 mg/mL) ºÍ25 mg/mL (·¶Î§Îª10 ~ 75 mg/mL) (P = 0.19)¡£COPD»¼ÕßÉîÎüÆø²»ÄÜÄæ×ªÖ§Æø¹ÜÊÕËõ [Ö§Æø¹ÜÊæÕŶÈΪ (3.9 +2.6) %£»µ¥Ñù±¾t¼ìÑéP = 0.15]; ¶ø½¡¿µ¶ÔÕÕ×éÉîÎüÆøºó³öÏÖÖ§Æø¹ÜÊæÕÅ [Ö§Æø¹ÜÊæÕŶÈΪ (13.7 +3.0) %£¬P = 0.000 3)£¬ÇÒÏÔÖø¸ßÓÚCOPD»¼Õß (P = 0.02)¡£¶ÔÓÚCOPD»¼Õߣ¬ÉîÎüÆøÓÕµ¼µÄÖ§Æø¹ÜÊæÕų̶ÈÓë·ÎÄÚÒ»Ñõ»¯Ì¼×ªÒÆÏµÊýÕ¼Ô¤¼ÆÖµµÄ°Ù·ÖÂÊÏà¹Ø (r = 0.53£¬P = 0.05)£¬¶øÓëÆøµÀ×èÈû (²ÉÓÃFEV1»òFEV1/FVCÀ´ÅжÏ) Î޹ء£ ½áÂÛ£ºÇá¶ÈCOPD»¼Õßȱ·¦ÓÉÉîÎüÆøµ¼ÖÂÖ§Æø¹ÜÊæÕŵÄÄÜÁ¦¡£ÎÒÃÇÍÆ²â£¬ÕâÒ»²¡ÀíÉúÀí¸Ä±äÓëÆäÂý ÐÔºôÎüµÀÖ¢×´µÄÐγɺÍÑÏÖØ³Ì¶ÈÓйء£ ¹Ø¼ü´Ê£ºÀÏÄê (aging); Ö§Æø¹Ü×èÈû (bronc-hial obstruction); Ö§Æø¹ÜÊÕËõ (bronchoconstriction); Ö§Æø¹ÜÊæÕÅ (bronchodilation); ÂýÐÔ×èÈûÐԷβ¡ (COPD); ÉîÎüÆø (deep inspiration); ÒÒõ£µ¨¼î (methocholine)
£¨Ð»¿¡¸Õ Ò룻ÐìÓÀ½¡ У£© ¡¾Ó¢ÎÄÔ¼þÇë²ÎÔÄChest, 2004; 125: 2029-2035¡¿
COPD»¼ÕßµÄÄÍÁ¦ºÍÁ¦Á¿ÑµÁ·
M. Jeffery Mador, MD; Erkan Bozkanat, MD; Ajay Aggarwal, MD; Mary Shaffer, NP; and Thomas J. Kufel, MD, FCCP From the Division of Pulmonary, Critical Care and Sleep Medicine (Drs. Bozkanat, Aggarwal, Kufel, and Mador), State University of New York at Buffalo, and the Veterans Affairs Western New York Healthcare System (Ms. Shaffer, and Drs. Mador and Kufel), Buffalo, NY. Correspondence to: M. Jeffery Mador, MD, Associate Professor of Medicine, Division of Pulmonary, Critical Care & Sleep Medicine, Section 111S, Veterans Administration Medical Center, 3495 Bailey Ave, Buffalo, NY 14215; e-mail: mador@acsu. buffalo. edu
Ä¿µÄ£º²ÉÓÃËæ»úÊÔÑé·½·¨£¬±È½ÏCOPD»¼Õßµ¥´¿ÄÍÁ¦ÑµÁ·ÓëÄÍÁ¦½áºÏÁ¦Á¿ÁªºÏѵÁ·µÄЧ¹û¡£ ·½·¨£º24Àý»¼ÕßÍê³ÉÏÂÁÐÑо¿£º11ÀýÈëÑ¡ÁªºÏѵÁ·×é [(FEV1Ϊ (x£ ±sx£ ) (45 ± 5) %Ô¤¼ÆÖµ]£¬13ÀýÈëÑ¡ÄÍÁ¦ÑµÁ·×é [FEV1Ϊ(40 +4) %Ô¤¼ÆÖµ£©¡£ÔÚ¿µ¸´ÑµÁ·Ç°ºó·Ö±ð²âÁ¿¼¡Á¦¡¢Éú»îÖÊÁ¿¡¢Ô˶¯ÄÜÁ¦ ºÍ¹ÉËÄÍ·¼¡Æ£ÀÍÐÔµÈÖ¸±ê¡£ ½á¹û£ºÁªºÏѵÁ·ÏÔÖøÌá¸ß¹ÉËÄÍ·¼¡ (23.6%)¡¢Ð¡Íȼ¡ (26.7%)¡¢ÐØ´ó¼¡ (17.5%)ºÍ±³À«¼¡ (20%) ¼¡Á¦£»¶øµ¥´¿ÄÍÁ¦ÑµÁ·²»ÄÜÏÔÖø¸ÄÉÆ¼¡Á¦£º¹ÉËÄÍ·¼¡£¨½µµÍ 1.1£¥£©¡¢Ð¡Íȼ¡£¨Ìá¸ß12.2£¥£©¡¢ÐØ´ó¼¡ (Ìá¸ß7.8%) ºÍ±³À«¼¡ (½µµÍ2.8 %)¡£ÁªºÏѵÁ·×é¹ÉËÄÍ·¼¡ºÍ±³À«¼¡¼¡Á¦µÄÔö¼ÓÏÔÖø¸ßÓÚÄÍÁ¦Ñµ Á·×飬¶øÐ¡Íȼ¡ºÍÐØ´ó¼¡¼¡Á¦µÄ¸Ä±äÔÚÁ½×é¼äÎÞÏÔÖøÐÔ²îÒì¡£¿µ¸´ÑµÁ·ºóÁ½×éµÄ 6 min²½ÐоàÀë¡¢ÄÍÁ¦Ô˶¯Ê±¼äºÍÉú»îÖÊÁ¿ (²ÉÓÃÂýÐÔºôÎü¼²²¡Îʾí²â¶¨) ¾ùÃ÷ÏÔÌá¸ß£¬µ«Ìá¸ßµÄ³Ì¶ÈÔÚÁ½×éÖ®¼äÎÞÏÔÖøÐÔ²îÒì¡£¿µ¸´ÑµÁ·ºó¹ÉËÄÍ·¼¡Æ£ÀÍ³Ì¶È (ͨ¹ý²â¶¨Ô˶¯Ç°ºó¹ÉËÄÍ·¼¡Ç¿Ö±Á¦½øÐÐÆÀ¹À) ÔÚÁ½×éÖ®¼äÒ²ÎÞÏÔÖøÐÔ²îÒì¡£ ½áÂÛ£ºÁ¦Á¿ÑµÁ·¿ÉÒýÆðÀÏÄêCOPD»¼Õß¼¡Á¦µÄÏÔÖø¸ÄÉÆ¡£È»¶ø£¬Óëµ¥´¿ÄÍÁ¦ÑµÁ·Ïà±È£¬ÕâÖÖ¼¡Á¦ µÄÌá¸ß²¢²»ÄÜʹ»¼ÕßÔÚÉú»îÖÊÁ¿¡¢Ô˶¯ÄÜÁ¦ºÍ¹ÉËÄÍ·¼¡Æ£Àͳ̶ȵȷ½Ãæ»ñµÃ¶îÍâµÄ¸ÄÉÆ¡£ ¹Ø¼ü´Ê£ºÑµÁ· (exercise); Ô˶¯ÁÆ·¨ (exercise therapy); ¼¡Èâ (muscle); ¹Ç÷À (skeletal); ·Î¼²²¡ (pulmonary disease); ÂýÐÔ×èÈûÐÔ (chronic obstructive); ¿µ¸´ (rehabilitation)
£¨Ð»¿¡¸Õ Ò룻ÐìÓÀ½¡ У£© ¡¾Ó¢ÎÄÔ¼þÇë²ÎÔÄChest, 2004; 125: 2036-2045¡¿
³ôÑõ±©Â¶¶ÔÏø´»¼ÕßÎüÈë±äÓ¦ÔËùÖÂÆøµÀ·´Ó¦ÐÔµÄÓ°Ïì
Lisa L. Chen, MD; Ira B. Tager, MD, MPH; David B. Peden, MD; Dorothy L. Christian, BA; Ronald E. Ferrando, MA; Barbara S. Welch, BS; and John R. Balmes, MD, FCCP From the Lung Biology Center, Center for Occupational and Environmental Health (Drs. Chen and Balmes, Ms. Christian, Mr. Ferrando, and Ms. Welch), Cardiovascular Research Institute, and Medical Service, San Francisco General Hospital, University of California, San Francisco, CA; Division of Public Health Biology and Epidemiology (Dr. Tager), School of Public Health, University of California, Berkeley, CA; and Center for Environmental Medicine and Lung Biology (Dr. Peden), Department of Pediatrics, University of North Carolina, Chapel Hill, NC. Correspondence to: John R. Balmes, MD, FCCP, University of California, San Francisco, Box 0843, San Francisco, CA 94143-0843; e-mail: jbalmes@itsa. ucsf. edu
±³¾°£º¹ØÓÚ³ôÑõ¶ÔÖÂÃôµÄÏø´»¼ÕßÎüÈë±äÓ¦ÔËùÖÂÔçÆÚÖ§Æø¹ÜÊÕËõ·´Ó¦µÄÓ°Ï죬²»Í¬µÄÈËÌå±äÓ¦Ô ¼¤·¢¶ÔÕÕÑо¿ÓÐ×ÅÏ໥ì¶ÜµÄ½á¹û¡£·Î¹¦ÄܲÎÊý²¢²»Ò»¶¨ÄÜ·´Ó³ÎüÈë³ôÑõ»ò±äÓ¦Ô¶ÔÆøµÀÑ×Ö¢µÄÓ°Ïì¡£ Ä¿µÄ£º±¾ÊµÑéÖ¼ÔÚµ÷²é³ôÑõ±©Â¶ÊÇ·ñÄÜÔöÇ¿ÖÂÃôÏø´»¼Õß¶ÔÎüÈëÎÝÄÚ³¾òýËùÖµÄÔçÆÚÖ§Æø¹ÜÊÕËõ·´ Ó¦ÒÔ¼°ÍíÆÚÆøµÀÑ×Ö¢·´Ó¦¡£ Éè¼Æ£ºËæ»ú¡¢¾ùºâÅä¶Ô¡¢½»²æÑо¿¡£ µØµã£ºÈËÌ屩¶ʵÑéÊÒ¡£ ·½·¨£ºÈ¡²»Í¬µÄÈÕ×Ó, 14Àý»¼ÕßÔÚÔ˶¯Öб©Â¶ÓÚ0.2¡Á10-6 (0.2 ppm) µÄO3»ò¾¹ýÂËµÄ¿ÕÆø1 h£¬È»ºóÒÔË«±¶¼ÁÁ¿µÄ·Û³¾òý (DF) ±äÓ¦Ô½øÐм¤·¢ (½á¹ûÒÔÒýÆðFEV1Ͻµ15 %µÄDF¼¤·¢Å¨¶È±íʾ£¬PC15)¡£ÔÚ±äÓ¦Ô¼¤·¢ºó 6 h£¬ÐÐÖ§Æø¹Ü·ÎÅݹàÏ´¡¢½ü¶ËÆøµÀ¹àÏ´ (PAL) ºÍÖ§Æø¹Ü»î¼ì¡£µÚ2´Î³ôÑõ±©Â¶/±äÓ¦Ô¼¤·¢/Ö§Æø¹Ü¾µ¼ì²éÖÁÉÙÔÚµÚÒ»´ÎÊÔÑé 4 wkºó½øÐС£ ½á¹û£º±äÓ¦Ô¼¤·¢ºó£¬ÔÚ³ôÑõºÍ¿ÕÆø±©Â¶×éÍíÆÚÑ×Ö¢·´Ó¦µÄϸ°ûѧºÍÉú»¯Ö¸±ê²îÒìÎÞÏÔÖøÐÔ (¾¡¹Ü³ôÑõ±©Â¶×éPALÒºÖÐÓÐÖÐÐÔÁ£Ï¸°ûÔö¶àµÄÇ÷ÊÆ£¬P = 0.06)¡£ ´ÓÕû×éÀ´¿´£¬³ôÑõ±©Â¶×éºÍ¿ÕÆø±©Â¶×éµÄPC15 ²îÒì²¢ÎÞÏÔÖøÐÔ¡£È»¶ø£¬³ôÑõÖÂFEV1½µµÍ×î¶àµÄ»¼ÕßÔÚ³ôÑõ±©Â¶ºóÓÐ½ÏµÍµÄ PC15¡£ ½áÂÛ£º±©Â¶ÓÚÏà¶ÔµÍŨ¶ÈµÄ³ôÑõ²»ÄÜÔöÇ¿´ó¶àÊýÏø´»¼ÕßÎüÈë±äÓ¦ÔËùÖµÄÍíÆÚÆøµÀÑ×Ö¢ºÍÔçÆÚÖ§ Æø¹ÜÊÕËõ·´Ó¦¡£È»¶ø£¬ÎÒÃǵĽá¹ûµÄÈ·Ò²Ìáʾ£¬³ôÑõ±©Â¶¿ÉʹijЩÑÇ×éµÄÏø´»¼Õß¶ÔÎüÈëÐÔ±äÓ¦Ô µÄÃô¸ÐÐÔÔö¸ß¡£ ¹Ø¼ü´Ê£ºÆøµÀÑ×Ö¢ (airway inflammation); ±äÓ¦Ô¼¤·¢ (allergen challenge); Ïø´ (asthma); Ö§Æø¹Ü·ÎÅݹàÏ´ (BAL); ³ôÑõ (ozone)
£¨Ðì·å Ò룻Éò»ªºÆ У£© ¡¾Ó¢ÎÄÔ¼þÇë²ÎÔÄChest, 2004; 125: 2328-2335¡¿ |
||
| Copyright (c) 2003-2006 Everwell Corporation(USA). Terms Of Use | Privacy Guidelines | ||||